



## Javier Martin Broto

Generated from: Editor CVN de FECYT

Date of document: 20/03/2020

**v 1.4.0**

80568224a509ac22d7ad18cde2e9f428

This electronic file (PDF) has embedded CVN technology (CVN-XML). The CVN technology of this file allows you to export and import curricular data from and to any compatible data base. List of adapted databases available at: <http://cvn.fecyt.es/>



## Summary of CV

This section describes briefly a summary of your career in science, academic and research; the main scientific and technological achievements and goals in your line of research in the medium -and long- term. It also includes other important aspects or peculiarities.

Dr Javier Martin Broto is a medical oncologist at the University Hospital Virgen del Rocío, and he is leading, at the Instituto de Biomedicina de Sevilla (IBIS), Seville (Spain) the lab team of the Advanced Therapies and Biomarkers in Sarcomas (TERABIS). He was born 53 years ago in Huesca province, Spain. He studied Medicine between 1982 and 1988 in the School of Medicine of Zaragoza, obtaining the official title of Specialist in Medical Oncology in Son Dureta Hospital, Palma de Mallorca, in 1994 after successfully passing a national exam. From 1994 to 2014 devoted to sarcoma care in this Hospital that became part of Center of Reference for Sarcoma.

From September 2014 he moved to University Hospital of Virgen del Rocío in Sevilla to coordinate the multidisciplinary sarcoma team and to apply for a selective number of centers of reference in Sarcoma Care in our Country. Finally our Center was accredited as National Health System Reference Center for Sarcoma Care (along with other 4 Hospitals). Likewise our Center is one accredited within ERN (European Network for Rare Diseases) as European Center of Reference in Sarcoma from 2017.

Founder Member of The Spanish Group for Research on Sarcomas (GEIS) in 1994 and currently vice-chairman of this group from 2019 (He was GEIS Chairman from 2010 to 2018). He obtained PhD degree on Molecular Biology in 2010 focusing on molecular prognostic biomarkers in GIST. Member of American Society of Clinical Oncology (ASCO), of European Society of Medical Oncology (ESMO) where is chair of sarcoma track, of Connective Tissue Oncology Society (CTOS), of Sociedad Española de Oncología Médica (SEOM). ESMO Faculty member in Sarcomas from 2010 and he was member of board directors of CTOS from 2014 to 2018. He is member of Steering committee of EURACAN network. Currently he combines clinical sarcoma assistance with translational research, leading a basic research team in the lab. Additionally, he's running and designing several trials on sarcoma 2 patients, some of them as coordinator at national and international level. He is the author/coauthor of more than 100 manuscripts in sarcoma including first author in journals as Journal Clinical Oncology, Lancet Oncology, JAMA Oncology, Annals of Oncology, and Molecular Cancer Therapeutics among others. He is leading the consortium SELNET through Horizon 2020 grant; this network involves LatinAmerican and European countries.



## General quality indicators of scientific research

This section describes briefly the main quality indicators of scientific production (periods of research activity, experience in supervising doctoral theses, total citations, articles in journals of the first quartile, H index...). It also includes other important aspects or peculiarities.

<b>Citation Index</b>	Total	Since 2012
Citations	6393	3993
h-index	40	31
i10-index	117	78

**Javier Martin Broto**

Surname(s): **Martin Broto**  
 Name: **Javier**  
 DNI: **18018895M**  
 ORCID: **0000-0001-7350-6916**  
 ResearcherID: **AAI-2313-2019**  
 Date of birth: **23/06/1964**  
 Gender: **Male**  
 Land line phone: **955923113 - 302113**  
 Email: **jmartin@mustbesevilla.org**

**Current professional situation**

**Employing entity:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency  
**Professional category:** Responsable Investigator (PI)  
**Start date:** 2015

**Employing entity:** INSTITUTO DE BIOMEDICINA DE SEVILLA  
**Professional category:** Adjunto Oncología Medica N° Colegiado 0704499  
**Start date:** 01/09/2014  
**Type of contract:** Permanent employment **Dedication regime:** Full time contract  
**Primary (UNESCO code):** 240000 - Life Science  
**Secondary (UNESCO code):** 240000 - Life Science  
**Tertiary (UNESCO code):** 320000 - Medical Science  
**Identify key words:** Natural sciences and health sciences

**Previous positions and activities**

	<b>Employing entity</b>	<b>Professional category</b>	<b>Start date</b>
<b>1</b>	Grupo Español de investigación en Sarcomas	Presidente	2010
<b>2</b>	Hospital Universitario Son Espases	Oncología Médica	01/11/2010
<b>3</b>	Hospital Universitario Son Dureta	Oncología Médica	01/01/1994

**1** **Employing entity:** Grupo Español de investigación en Sarcomas  
**Professional category:** Presidente  
**Start-End date:** 2010 - 2018 **Duration:** 8 years

**2** **Employing entity:** Hospital Universitario Son Espases **Type of entity:** Hospital  
**Professional category:** Oncología Médica  
**Start-End date:** 01/11/2010 - 31/08/2014



**3** **Employing entity:** Hospital Universitario Son Dureta  
**Professional category:** Oncología Médica  
**Start-End date:** 01/01/1994 - 31/10/2010

**Type of entity:** Healthcare Institutions



## Education

### University education

#### 1st and 2nd cycle studies and pre-Bologna degrees

- 1 Name of qualification:** Residency in Medical Oncology  
**Degree awarding entity:** Hospital Universitario Son Dureta  
**Type of entity:** Healthcare Institutions  
**Date of qualification:** 31/07/1994
- 2 Name of qualification:** Degree in Medicine  
**Degree awarding entity:** Universidad de Zaragoza  
**Date of qualification:** 30/06/1988

#### Doctorates

**Doctorate programme:** PhD in Health Sciences  
**Degree awarding entity:** Universidad de las Islas Baleares  
**Type of entity:** University  
**Date of degree:** 14/07/2009

### Language skills

Language	Listening skills	Reading skills	Spoken interaction	Speaking skills	Writing skills
French		B1	A1	A1	A1
Catalan		C1	C1	C1	C1
Spanish		C1	C1	C1	C1
English		C1	C1	C1	C1

## Teaching experience

### General teaching experience

- 1 Name of the course:** 'Curso Avanzado de Sarcoma para residentes'  
**Start date:** 2010  
**End date:** 2015  
**Entity:** GEIS
- 2 Name of the course:** Oncología Médica. Tutor de residentes, Profesional docente  
**University degree:** Oncología Médica  
**Start date:** 1995  
**End date:** 2014  
**Entity:** Hospital Universitario Son Dureta



**Faculty, institute or centre:** 527 horas

- 3 Name of the course:** Biología del cáncer. Sarcomas.  
**University degree:** Máster de la Universitat de les Illes Balears  
**Start date:** 2012 **End date:** 2013
- 4 Name of the course:** Máster de la Universidad de Las Islas Baleares en Biología del cáncer. Capítulos sobre sarcomas. Mayo/2013  
**University degree:** Máster de la Universidad de Las Islas Baleares en Biología del cáncer  
**Start date:** 2012 **End date:** 2013  
**Entity:** Universidad de Las Islas Baleares  
**Faculty, institute or centre:** Profesosr 14 creditos
- 5 Name of the course:** "GIST: Diagnosis, staging and therapy"  
**Entity:** ESMO-ESO Course on Medical Oncology for Medical Students
- 6 Name of the course:** Terapias en sarcoma: sarcoma partes blandas; GI y óseo  
**Entity:** Curso de Patología Molecular y terapia en sarcoma del Centro de Estudios Biosanitarios

### Experience supervising doctoral thesis and/or final year projects

- 1 Project title:** Analisis de FasR/FasL como factor pronostico/predictivo en GIST localizado. Revision cientifica del proyecto de investigacion  
**Entity:** Universidad de Sevilla **Type of entity:** University  
**Student:** Omar Saavedra Santa Gadea  
**Date of reading:** 2015
- 2 Project title:** Analisis de FasR/FasL como factor pronostico/predictivo en GIST. Enfermedad localmente avanzada y metastasica.Revision cientifica del proyecto de investigacion  
**Entity:** Universidad de Sevilla **Type of entity:** University  
**Student:** Natalia Palazon Carrio  
**Date of reading:** 2015
- 3 Project title:** Análisis exploratorio de factores genéticos predictivos de respuesta al tratamiento en sarcoma de Ewing metastático  
**Entity:** Universidad de Sevilla **Type of entity:** University  
**Student:** Alejandro GONZALEZ Forastero
- 4 Project title:** Análisis exploratorios de factores moleculares pronósticos en tumores desmoides  
**Entity:** Universidad de Sevilla **Type of entity:** University  
**Student:** Johanna Benedetti Pedroza



## Student tutorials

**Name of the programme:** Practicas externas Fin Grado Biotecnología  
**Entity:** INSTITUTO DE BIOMEDICINA DE SEVILLA      **Type of entity:** State agency  
**Number of recognized hours/ECTS credits:** 120  
**Number of tutored students:** 1

## Educational or pedagogical publications, books, articles, etc.

- 1** Participation and promoter of GEIS and SEOM guidelines of GIST, Soft-tissue sarcoma and bone sarcomas.  
**Name of the materials:** Clinical Guidelines
- 2** Participation in all the clinical guidelines editions in sarcomas of the European Society of Medical Oncology (ESMO). ESMO.  
**Name of the materials:** Clinical Guidelines

## Other activities/achievements not included above

- 1** **Description of the activity:** XIII International GEIS Symposium  
**Organising entity:** Grupo Español de investigación en sarcoma  
**End date:** 21/11/2015
- 2** **Description of the activity:** VII Curso Avanzado de Sarcoma para residentes  
**End date:** 13/06/2015
- 3** **Description of the activity:** Participe en International task force of Chordoma and GIST

## Healthcare experience

### Other activities/achievements not included above

- 1** **Other relevant activities:** Coordinador del Comité Multidisciplinar de tumores músculo-esqueléticos (COTMES) del Hospital Son Espases y Son Dureta  
**Entity where project took place:** Hospital Son Espases y Son Dureta  
**End date:** 2014
- 2** **Other relevant activities:** Obtención de Evaluación positiva por parte de la Agència de Qualitat Universitària de les Illes Balears formulada por el Comité de Ciencias de la Salud  
**Entity where project took place:** Agència de Qualitat Universitària de les Illes Balears  
**End date:** 2011





- 3 **Other relevant activities:** Conferenciante en foros académicos con unas 40-60 conferencias/año y advisor de expertos en sarcomas.
- 4 **Other relevant activities:** Faculty member de sarcomas en ESMO (desde 2009)
- 5 **Other relevant activities:** Member of Board of directors in Connective Tissue Oncology Society (CTOS) y de la Sociedad Española de Oncología Médica (SEOM)
- 6 **Other relevant activities:** Miembro de las plataformas Euroewing, Euramos y Eurosarc
- 7 **Other relevant activities:** Sinergias con varios equipos de investigación, tanto nacionales como internacionales, con reconocido prestigio en investigación clínica y traslacional en Sarcomas
- 8 **Other relevant activities:** Socio de: American Society of Clinical Oncology (ASCO)

## Scientific and technological experience

### Scientific or technological activities

#### R&D projects funded through competitive calls of public or private entities

- 1 **Name of the project:** Improving neoadjuvant therapy in high-risk sarcomas  
**Geographical area:** European Union  
**Degree of contribution:** Researcher  
**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency  
**Name principal investigator (PI, Co-PI....):** Robin Jones; Valerie Brunton; Javier Martin Broto  
**Funding entity or bodies:**  
Cancer Research UK  
Fondazione AIRC **Type of entity:** Associations and Groups  
Asociación Española Contra el Cáncer **Type of entity:** Associations and Groups  
**City funding entity:** Valencia, Valencian Community, Spain  
**Type of participation:** Team member  
**Start-End date:** 2019 - 2023  
**Total amount:** 559.250 €
- 2 **Name of the project:** Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network (SELNET)  
**Degree of contribution:** Coordinator of total project, network or consortium  
**Type of entity:** State agency



**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA

**City of entity:** Sevilla, Andalusia, Spain

**Name principal investigator (PI, Co-PI....):** Javier Martin Broto

**Type of participation:** Principal investigator

**Start-End date:** 2019 - 2023

**Duration:** 4 years

**Total amount:** 3.100.000 €

**3 Name of the project:** Agentes antiangiogenicos en Tumor Fibroso Solitario: nuevas ideas en el mecanismo de acción

**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency

**Name principal investigator (PI, Co-PI....):** Javier Martin Broto

**Type of participation:** Principal investigator

**Start-End date:** 2019 - 2022

**Total amount:** 111.000 €

**4 Name of the project:** Phase I clinical trial of Olaratumab plus Trabectedin in advanced soft-tissue sarcoma patients (OLATRASTS)

**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency

**Name principal investigator (PI, Co-PI....):** Javier Martin Broto

**Start-End date:** 2019 - 2020

**Total amount:** 75.000 €

**5 Name of the project:** Exploring vasculature-related targets in angiosarcoma: an open road to new clinical trials

**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency

**Name principal investigator (PI, Co-PI....):** Javier Martin Broto

**Start-End date:** 2018 - 2020

**Total amount:** 27.000 €

**6 Name of the project:** New insights in the mechanisms of action of cisplatin in rhabdomyosarcomas: waking up an old drug for a fresh purpose

**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency

**Name principal investigator (PI, Co-PI....):** Javier Martin Broto

**Start-End date:** 2018 - 2020

**Total amount:** 52.000 €

**7 Name of the project:** REGISTRI. Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectableKIT/PDGFR Wild Type GIST

**Name principal investigator (PI, Co-PI....):** Javier Martín-Broto; Italian coordinator Dr Elena Fumagalli

**Nº of researchers:** 18

**Start-End date:** 2015 - 2020

**Total amount:** 351.030 €

**8 Name of the project:** Consortium – International Clinical Trials to Improve Survival from Ewing’s Sarcoma

**Nº of researchers:** 31

**Funding entity or bodies:**



## SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA

**Start-End date:** 2013 - 2020

- 9** **Name of the project:** Exploración de factores pronósticos moleculares relacionados con genotipo e inmunomodulación en GIST localizados. PI15/01254  
**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency  
**City of entity:** sevilla, Andalusia, Spain  
**Name principal investigator (PI, Co-PI....):** JAVIER MARTIN BROTO  
**Nº of researchers:** 12  
**Funding entity or bodies:** Instituto de Salud Carlos III .Subprograma de proyectos de investigacion en salud (AES 2015).  
**Start-End date:** 01/12/2015 - 31/12/2018  
**Total amount:** 62.315 €
- 10** **Name of the project:** A PHASE II OPEN-LABEL TRIAL OF PAZOPANIB ADMINISTERED AS A SINGLE AGENT IN PATIENTS WITH UNRESECTABLE OR METATSTATIC SOLITARY FIBROUS TUMOR (SFT) AND EXTRASKELETAL MYXOID CHONDROSARCOMA (EMC)  
**Entity where project took place:** Complejo Hospitalario Virgen del Rocío-IBIS  
**Nº of researchers:** 14  
**Funding entity or bodies:** GSK-GEIS  
**Start-End date:** 2014 - 2018  
**Total amount:** 570.000 €
- 11** **Name of the project:** International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumors  
**Entity where project took place:** Complejo Hospitalario Virgen del Rocío **Type of entity:** Healthcare Institutions  
**Nº of researchers:** 17  
**Funding entity or bodies:** SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA  
**Start-End date:** 2013 - 2018  
**Total amount:** 238.000 €
- 12** **Name of the project:** Análisis exploratorio de factores moleculares de inmunomodulación y apoptosis en sarcomas y su posible papel pronóstico.  
**Name principal investigator (PI, Co-PI....):** Nadia Hindi Muñiz  
**Start-End date:** 2015 - 2017  
**Total amount:** 8.000 €
- 13** **Name of the project:** Phase I-II trial exploring the combination of trabectedin plus radiotherapy in soft tissue sarcoma patients.  
**Entity where project took place:** Complejo Hospitalario Virgen del Rocío-IBIS  
**Nº of researchers:** 19  
**Funding entity or bodies:** Pharma Mar, S.A. **Type of entity:** Business  
**City funding entity:** Colmenar Viejo, Community of Madrid, Spain  
**Start-End date:** 2014 - 2017



**Total amount:** 623.410 €

- 14 Name of the project:** EUROSARC - EUROPEAN CLINICAL TRIALS IN RARE SARCOMAS WITHIN AN INTEGRATED TRANSLATIONAL TRIAL NETWORK  
**Name principal investigator (PI, Co-PI....):** JEAN YVES BLAY  
**Nº of researchers:** 17  
**Funding entity or bodies:**  
SÉPTIMO PROGRAMA MARCO DE LA UE  
**Start-End date:** 2011 - 2016 **Duration:** 5 years  
**Participating entity/entities:** 9 M EUROS; ACADEMISCH ZIEKENHUIS LEIDEN; AZIENDA UNITA SANITARIA N9 TREVISO; EORTC; FONDAZIONE IRCCS; INSTITUT BERGONIE; INSTITUT GUSTAVE ROUSSY; ISTITUTO ORTOPEDICO RIZZOLI; LYON INGENIERIE PROJETS. IMPORTE: 5; MARIA SKLODOWSKA MEMORIAL CANCER CENTER; OXFORD GENE TECH; SPAEN; Servei de Salut de les Illes Balears; UNIV. DE SALAMANCA; UNIV. OF BIRMINGHAM; UNIVERSITAET HEIDELBERG; UNIVERSITE LYON 1 CL. BERNARD; UNIVERSITY OF OXFORD
- 15 Name of the project:** Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye quimioterapia estándar vs histotipo-dirigida neoadyuvante  
**Nº of researchers:** 18  
**Funding entity or bodies:**  
SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA  
**Start-End date:** 2011 - 2016  
**Total amount:** 102.000 €
- 16 Name of the project:** EC10-150 ENSAYO FASE I/II MULTICÉNTRICO Y PROSPECTIVO DE NILOTINIB Y ADRIAMICINA COMO TRATAMIENTO NEOADYUVANTE EN LIPOSARCOMAS Y LEIOMIOSARCOMA DE RETROPERITONEO.  
**Name principal investigator (PI, Co-PI....):** JAVIER MARTÍN  
**Nº of researchers:** 20  
**Funding entity or bodies:**  
MINISTERIO DE SANIDAD  
**Start-End date:** 15/03/2011 - 30/06/2015 **Duration:** 2 years  
**Participating entity/entities:** COMPLEJO HOSPITALARIO DE NAVARRA; HOSPITAL LA PAZ DE MADRID; HOSPITAL MARQUÉS DE VALDECILLA; HOSPITAL SON ESPASES; HOSPITAL VALL D'HEBRON; HOSPITAL VIRGEN DEL ROCÍO; Hospital Universitario de Canarias; INSTITUTO VALENCIANO DE ONCOLOGÍA; MIGUEL SERVET; PUERTA DE HIERRO; XERAL CIES DE VIGO. IMPORTE: 400.000 EUROS  
**Total amount:** 400.000 €
- 17 Name of the project:** Sarcomas de alto riesgo, de partes blandas, de extremidades y de Tronco superficial, en estadio localizado: abordaje integrado Incluyendo quimioterapia adyuvante de tres o cinco ciclos. Estudio prospectivo controlado randomizado fase III. Estudio colaborativo con el Grupo italiano de Sarcomas (ISG)  
**Nº of researchers:** 18  
**Funding entity or bodies:**  
ISG  
**Start-End date:** 2011 - 2015  
**Total amount:** 70.000 €



- 18 Name of the project:** Análisis mutacional de tumores de estroma gastrointestinal c-kit negativos o débilmente positivos. correlación clínica y patológica  
**Nº of researchers:** 1  
**Funding entity or bodies:**  
Novartis Farmacéutica, S.A. - GRUPO GEIS  
**Start-End date:** 2007 - 2008  
**Total amount:** 18.000 €
- 19 Name of the project:** Proyecto iNTER Platform (International Network of Teleconsultation Excellence & Referral)  
**Nº of researchers:** 1  
**Funding entity or bodies:**  
CONSELLERIA D'ECONOMIA, HISENDA I INNOVACIO- DIRECCION GENERAL DE RECERCA, DESENVOLUPAMENT TECNOLÒGIC I INNOVACION (GOVERN DE LES ILLES BALEARS)  
**Start-End date:** 2007 - 2008  
**Total amount:** 12.000 €
- 20 Name of the project:** Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreexpresión CDK4.  
**Entity where project took place:** Hospital Universitario Virgen del Rocío  
**City of entity:** Sevilla, Andalusia, Spain  
**Name principal investigator (PI, Co-PI....):** Javier Martín Broto  
**Start date:** 2017  
**Total amount:** 150.000 €
- 21 Name of the project:** Immunomodulatory role of Pazopanib in Soft-tissue Sarcoma  
**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency  
**City of entity:** Sevilla, Andalusia, Spain  
**Name principal investigator (PI, Co-PI....):** Javier Martín Broto  
**Start date:** 2017  
**Total amount:** 48.876,05 €
- 22 Name of the project:** Phase I-II Trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.  
**Entity where project took place:** Hospital Universitario Virgen del Rocío  
**City of entity:** Sevilla, Andalusia, Spain  
**Name principal investigator (PI, Co-PI....):** Javier Martín Broto  
**Start date:** 2017  
**Total amount:** 80.000 €
- 23 Name of the project:** Phase II Trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma.  
**Entity where project took place:** Hospital Universitario Virgen del Rocío  
**City of entity:** Sevilla, Andalusia, Spain  
**Start date:** 2017  
**Total amount:** 75.000 €
- 24 Name of the project:** Targeting the tumour microenvironment in liposarcoma with Eribulin as backbone  
**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency



**Name principal investigator (PI, Co-PI....):** Javier Martín Broto

**Nº of researchers:** 6

**Funding entity or bodies:**

Eisai.co., Ltd.

**Type of entity:** Business

**Start date:** 2017

**Total amount:** 48.000 €

**25 Name of the project:** Targeting tumour microenvironment in sarcoma

**Entity where project took place:** INSTITUTO DE BIOMEDICINA DE SEVILLA **Type of entity:** State agency

**City of entity:** Sevilla,

**Name principal investigator (PI, Co-PI....):** Javier Martín Broto

**Nº of researchers:** 6

**Funding entity or bodies:**

Pharma Mar, S.A.

**Type of entity:** Business

**City funding entity:** Colmenar Viejo, Community of Madrid, Spain

**Start date:** 2017

**Total amount:** 41.628,64 €

**26 Name of the project:** REGISTRO DE SARCOMAS RAROS:HERRAMIENTA DE AYUDA PARA EVALUAR EL NUMERO DE CASOS DE CADA SUBTIPO Y SU ORIENTACION TERAPEUTICA POR EL GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS (GEIS). "SUBESTUDIO Nº 2: BUSQUEDA DE MOLECULAS DIANA RELEVANTES EN TUMORES DESMOIDES)

**Name principal investigator (PI, Co-PI....):** Rosa Alvarez; JM Trufero; Javier Martin Broto

**Start date:** 2016

**27 Name of the project:** ESTUDIO OBSERVACIONAL, RETROSPECTIVO Y MULTICÉNTRICO PARA IDENTIFICAR LOS PERFILES DE PACIENTES QUE MÁS SE BENEFICIAN DEL TRATAMIENTO CON TRABECTEDINA EN SEGUNDA LÍNEA EN PACIENTES CON SARCOMA DE TEJIDOS BLANDOS, LOCALMENTE AVANZADOS O METASTÁTICOS, QUE HAN PROGRESADO A UN TRATAMIENTO DE PRIMERA LÍNEA." GEIS 38

**Name principal investigator (PI, Co-PI....):** JAVIER MARTIN BROTO; JAVIER MARTINEZ TRUFERO

**Start date:** 2015

**28 Name of the project:** EC11-444 ENSAYO FASE II MULTICÉNTRICO Y PROSPECTIVO CON GEMCITABINA Y RAPAMICINA EN SEGUNDA LÍNEA DE OSTEOSARCOMA METASTÁSICO.

**Name principal investigator (PI, Co-PI....):** JAVIER MARTÍN

**Nº of researchers:** 15

**Funding entity or bodies:**

MINISTERIO DE SANIDAD

**Start date:** 15/03/2012

**Duration:** 2 years

**Participating entity/entities:** HOSPITAL DE LA SANTA CREU I SANT PAU; HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS IMPORTE: 350.000 EUROS EUROS; HOSPITAL UNIVERSITARI SON ESPASES; HOSPITAL UNIVERSITARI VALL D'HEBRON INSTITUT CATALÀ D'ONCOLOGIA HOSPITALET; HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE DE VALENCIA; HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA; HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO; HOSPITAL XERAL CIES; Hospital Sant Joan de Déu; Hospital Universitario La Paz; Hospital Universitario Miguel Servet; Hospital Universitario Ramón y Cajal; Hospital Universitario de Canarias

**Total amount:** 350.000 €

- 29** **Name of the project:** TRA-050 ESTUDIO TRASLACIONAL ASOCIADO AL ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA VS TRABECTEDINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMAS DE PARTES BLANDAS AVANZADOS O METASTÁSICOS.  
**Name principal investigator (PI, Co-PI....):** JAVIER MARTÍN  
**Nº of researchers:** 2  
**Funding entity or bodies:**  
MINISTERIO DE SANIDAD  
**Start date:** 01/01/2010 **Duration:** 1 year - 11 months - 30 days  
**Participating entity/entities:** HOSPITAL SON ESPASES E INSTITUTO VALENCIANO DE ONCOLOGÍA  
IMPORTE: 58.000 EUROS  
**Total amount:** 58.000 €
- 30** **Name of the project:** ISA: INTER SUPPORT ACTION (INTERNATIONAL NETWORK OF TELECONSULTATION EXCELLENCE & REFERRAL)  
**Name principal investigator (PI, Co-PI....):** JAVIER MARTÍN  
**Nº of researchers:** 10  
**Funding entity or bodies:**  
SÉPTIMO PROGRAMA MARCO DE LA UE  
**Start date:** 01/09/2009 **Duration:** 2 years - 5 months - 27 days  
**Participating entity/entities:** C2C CONSULTORÍA. IMPORTE: 779.895 EUROS; CMF HEALTH MINISTRIES; DESARROLLO 2000 EN ÁFRICA; HOSPITAL DOCENTE DE TRUJILLO; HOSPITAL SON ESPASES; HOSPITAL VALL D'HEBRON; Hospital Sant Joan de Déu; INSTITUTO NACIONAL DE CANCEROLOGÍA DE MÉXICO; INSTITUTO VALENCIANO DE ONCOLOGÍA; UNIVERSIDAD DE NAIROBI  
**Total amount:** 779,9 €
- 31** **Name of the project:** Estudio de la combinación de inhibidores tirosina quinasas con quimioterapia en líneas celulares de sarcoma y GIST. Foco en el cronograma de administración para favorecer el efecto sinérgico  
**Nº of researchers:** 7  
**Funding entity or bodies:**  
GEIS (3ª Beca José Mª Buesa del Grupo GEIS de Ayuda a la Investigación en Sarcomas)  
**Total amount:** 6.000 €
- 32** **Name of the project:** Tumores del estroma gastrointestinal (GIST) localizados, de riesgo intermedio y alto, y completamente extirpados que expresan el receptor KIT: estudio aleatorizado controlado sobre el tratamiento adyuvante con mesilato de imatinib (Glivec) en comparación con la administración de ningún tratamiento después de la cirugía completa. Estudio colaborativo con la EORTC (European Organisation for Research and Treatment of Cancer).  
**Name principal investigator (PI, Co-PI....):** ANTONIO CASADO; ANDRES POVEDA  
**Nº of researchers:** 18  
**Funding entity or bodies:**  
European Organisation for Research and Treatment of Cancer **Type of entity:** 1  
**City funding entity:** Valencia, Valencian Community, Spain  
**Total amount:** 60.000 €

**R&D non-competitive contracts, agreements or projects with public or private entities**

- 1** **Name of the project:** International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma  
**Degree of contribution:** Researcher  
**Funding entity or bodies:**  
 SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA (FP7)  
**Start date:** 2014 **Duration:** 5 years  
**Total amount:** 238.000 €
- 2** **Name of the project:** Estudio del potencial antitumoral de un nuevo fármaco diana en sarcomas.  
**Nº of researchers:** 3  
**Funding entity or bodies:**  
 HOSPITAL UNIVERSITARIO SON ESPASES  
**Start date:** 2012 **Duration:** 1 year  
**Total amount:** 3.000 €
- 3** **Name of the project:** Análisis exhaustivo de GISTs wild type para hallar nuevas dianas terapéuticas  
**Nº of researchers:** 5  
**Funding entity or bodies:**  
 HOSPITAL UNIVERSITARIO SON ESPASES  
**Start date:** 2011 **Duration:** 2 years  
**Total amount:** 14.000 €

**Scientific and technological activities****Scientific production****Publications, scientific and technical documents**

- 1** Javier Martin Broto; J Cruz; N Penel; A Le Cesne; N Hindi; P Luna; DS Moura; D Bernabeu; E De Alava; JA Lopez Guerrero; J Dopazo; M Peña Chilet; A Gutierrez; P Collini; M Karanian; A Redondo; A Lopez Pousa; G Grignani; J Diaz Martin; D Marcilla; A Fernandez Serra; C Gonzalez Aguilera; PG Casali; JY Blay; S Stacchiotti. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncology. 21 - 3, pp. 456 - 466. 03/2020. ISSN 1470-2045  
**DOI:** 10.1016/S1470-2045(19)30826-5  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 25 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 35.386 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 48,82  
**Relevant publication:** Yes



- 2** Javier Martin Broto. Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. The Lancet Oncology. 21 - 1, pp. 16 - 17. 01/2020. ISSN 1470-2045  
**DOI:** 10.1016/S1470-2045(19)30679-5  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 1 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 35.386 **Journal in the top 25%:** Yes  
**Position of publication:** 59,1  
**Source of citations:** JCR **Citations:** 48,82  
**Relevant publication:** Yes
- 3** S Stacchiotti; S Ferrari; A Redondo; N Hindi; E Palmerini; MA Vaz Salgado; AM Frezza; PG Casali; A Gutierrez; A Lopez Pousa; G Grignani; A Italiano; A LeCesne; S Dumont; JY Blay; N Penel; D Bernabeu; E De Alava; M Karanian; C Morosi; S Brich; GP Dagrada; V Vallacchi; C Castelli; M Brenca; D Racanelli; R Maestro; P Collini; J Cruz; J Martin Broto. Pazopanib for treatment of advanced extraskelletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology. 20 - 9, pp. 1252 - 1262. 09/2019. ISSN 1470-2045  
**DOI:** 10.1016/S1470-2045(19)30319-5  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 30 **Corresponding author:** No  
**Total no. authors:** 30 **Category:** Science Edition - ONCOLOGY  
**Impact source:** JCR **Journal in the top 25%:** Yes  
**Impact index in year of publication:** 35.386 **Citations:** 48,82  
**Source of citations:** JCR  
**Relevant publication:** Yes
- 4** WD Tap; H Gelderblom; E Palmerini; J Desai; S Bauer; JY Blay; T Alcindor; K Ganjoo; J Martin Broto; CW Ryan; DM Thomas; C Peterfy; JH Healey; M Van de Sande; HL Gelhorn; DE Shurter; Q Wang; A Yver; HH Hsu; PS Lin; S Tong-Starksen; S Stacchiotti; AJ Wagner. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a raddomised phase 3 trial. Lancet. 394 - 40197, pp. 478 - 487. 08/2019. ISSN 0140-6736  
**DOI:** 10.1016/S0140-6736(19)30764-0  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 9 **Corresponding author:** No  
**Total no. authors:** 23 **Category:** Science Edition - ONCOLOGY  
**Impact source:** JCR **Journal in the top 25%:** Yes  
**Impact index in year of publication:** 59.102 **Citations:** 247,29  
**Source of citations:** JCR  
**Relevant publication:** Yes
- 5** Javier Martin Broto; David S Moura; Nadia Hindi. Pazopanib in the treatment of advanced solitary fibrous tumour-Autors'reply. Lancet Oncology. 20 - 3, pp. e128. 03/2019. ISSN 1470-2045  
**DOI:** 10.1016/S1470-2045(19)30080-4  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1 **Corresponding author:** Yes  
**Total no. authors:** 3 **Category:** Science Edition - ONCOLOGY  
**Impact source:** JCR **Journal in the top 25%:** Yes  
**Impact index in year of publication:** 35.386 **Citations:** 48.822  
**Source of citations:** JCR

**Relevant publication:** Yes

- 6** Javier Martin Broto; Silvia Stacchiotti; Antonio Lopez Pousa; Andres Redondo; Daniel Bernabeu; Enrique De Alava; Paolo G Casali; Antonine Italiano; Antonio Gutierrez; David S Moura; Maria Peña Chilet; Juan Diaz Martin; Michele Biscuola; Miguel Taron; Paola Collini; Dominique Ranchere Vince; Xavier Garcia Del Muro; Giovanni Griganani; Josefina Cruz. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. *Lancet Oncology*. 20 - 1, pp. 134 - 144. 01/2019. ISSN 1470-2045

**DOI:** 10.1016/S1470-2045(18)30676-4**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 1**Total no. authors:** 19**Corresponding author:** Yes**Impact source:** JCR**Category:** Science Edition - ONCOLOGY**Impact index in year of publication:** 35.386**Journal in the top 25%:** Yes**Source of citations:** JCR**Citations:** 48,82**Relevant publication:** Yes

- 7** David S Moura; Rafael Ramos; Antonio Fernandez Serra; Teresa Serrano; Julia Cruz; Ramiro Alvarez Alegret; Rosa Ortiz Duran; Luis Vicioso; Maria Luisa Gomez Dorronsoro; Xavier Garcia Del Muro; Javier Martinez Trufero; Jordi Rubio Casadevall; Isabel Sevilla; Nuria Lainez; Antonio Gutierrez; Cesar Serrano; Maria Lopez Alvarez; Nadia Hindi; Miguel Taron; Jose Antonio Lopez Guerrero; Javier Martin Broto. Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. *Oncotarget*. 3 - 9, pp. 17576 - 17588. 04/2018. ISSN 1949-2553

**DOI:** 10.18632/oncotarget.24799**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 21**Total no. authors:** 21**Corresponding author:** Yes**Impact source:** JCR**Category:** Science Edition - ONCOLOGY**Impact index in year of publication:** 5.168**Journal in the top 25%:** Yes**Source of citations:** JCR**Citations:** 30,24**Relevant publication:** Yes

- 8** S Stacchiotti; A Gronchi; P Fossati; T Akiyama; C Alapetite; M Baumann; J Y Blay; S Bolle; S Boriani; P Bruzzi; R Capanna; A Caraceni; R Casadei; V Colia; J Debus; T Delaney; A Desai; P Dileo; S Dijkstra; F Doglietto; A Flanagan; S Froelich; P A Gardner; H Gelderblom; Z L Gokaslan; R Haas; C Heery; N Hindi; P Hohenberger; F Hornicek; R Imai; L Jeys; R L Jones; B Kasper; A Kawai; M Krengli; A Leithner; I Logowska; J Martin Broto; D Mazzatenta; C Morosi; P Nicolai; O J Norum; S Patel; N Penel; P Picci; S Pilotti; S Radaelli; F Ricchini; P Rutkowski; S Scheipl; C Sen; E Tamborini; K A Thornton; B Timmermann; V Torri; P U Tunn; M Uhl; Y Yamada; D C Weber; D Vanel; P P Varga; C LA Vleggeert Lankamp; P G Casali; J Sommer. Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. *Annals of oncology*. 28 - 6, pp. 1230 - 1242. 06/2017. ISSN 0923-7534

**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 39**Total no. authors:** 65**Corresponding author:** No**Impact source:** JCR**Category:** Science Edition - ONCOLOGY**Impact index in year of publication:** 13.930**Journal in the top 25%:** Yes**Source of citations:** JCR**Citations:** 38,74**Relevant publication:** Yes

- 9** Alessandro Gronchi; Stefano Ferrari; Vittorio Quagliuolo; Javier Martin Broto; Antonio Lopez Pousa; Giovanni Griganani; Umberto Basso; Jean Yves Blay; Oscar Tendero; Robert Diaz Beveridge; Virginia Ferraresi; Iwona Lugowska; Domenico Franco Merlo; Valeria Fontana; Emanuela Marchesi; Davide Maria Donati; Elena Palassini; Emanuela Palmerini; Rita De Sanctis; Carlo Morosi; Silvia Stacchiotti; Silvia Bagué; Jean Michelle Coindre; Angelo Paolo Dei Tos; Piero Picci; Paolo Bruzzi; Paolo Giovanni Casali. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STs 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncology*. 18 - 6, pp. 812 - 822. 06/2017. ISSN 1470-2045  
**DOI:** 10.1016/S1470-2045(17)30334-0  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 4  
**Total no. authors:** 27 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 35.386 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 48,82  
**Relevant publication:** Yes
- 10** Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial. *JAMA Oncology*. 02/2020. ISSN 2374-2437  
**DOI:** 10.1001/jamaoncol.2019.6584  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 30 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 21.886 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 22,42
- 11** Javier Martin Broto; Nadia Hindi; David Moura DS. Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. *Future Oncology*. 15 - 26s, pp. 17 - 23. 09/2019. ISSN 1479-6694  
**DOI:** 10.2217/fo-2019-0490  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 3 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 2.279 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 4,05
- 12** G Fucà; Nadia Hindi; I Ray Coquard; V Colia; AP Dei Tos; Javier Martin Broto; M Brahmi; P Collini; D Lorusso; F Raspagliesi; MA Pantaleo; B Vincenzi; E Fumagalli; A Gronchi; PG Casali; R Sanfilippo. Treatment outcomes and sensitivity to hormone therapy of aggressive angiomyxoma: a multicenter, international, retrospective study. *Oncologist*. 24 - 7, pp. e536 - e541. 07/2019. ISSN 1083-7159  
**DOI:** 10.1634/theoncologist.2018-0338  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 6  
**Total no. authors:** 16 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 5.252 **Journal in the top 25%:** Yes

**Source of citations:** JCR**Citations:** 11,83

- 13** Javier Martin Broto; Nadia Hindi; J Cruz; J Martinez Trufero; C Valverde; LM De Sande; A Sala; L Bellido; A De Juan; J Rubió Casadevall; R Diaz Beveridge; R Cubedo; O Tendero; D Salinas; I Gracia; R Ramos; S Baguè; A Gutierrez; J Duran Moreno; A Lopez Pousa. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). *Oncologist*. 24 - 6, pp. e338 - e346. 06/2019. ISSN 1083-7159

**DOI:** 10.1634/theoncologist.2018-0121**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 1**Total no. authors:** 20**Corresponding author:** Yes**Impact source:** JCR**Category:** Science Edition - ONCOLOGY**Impact index in year of publication:** 5.252**Journal in the top 25%:** Yes**Source of citations:** JCR**Citations:** 11.831

- 14** Alessandro Gronchi; Nadia Hindi; Josefina Cruz; Jean-Yves Blay; Antonio Lopez Pousa; Antoine Italiano; Rosa Alvarez; Antonio Gutierrez; Inmaculada Rincon; Claudia Sangalli; Jose Luis Perez Aguiar; Jesus Romero; Carlo Morosi; Marie Pierre Sunyach; Roberta Sanfilippo; Cleofe Romagosa; Dominique Ranchere Vince; Paolo G. Casali; Javier Martin Broto. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *EClinicalMedicine*. 9 - 11, pp. 35 - 43. 03/2019. ISSN 2589-5370

**DOI:** 10.1016/j.eclinm.2019.03.007**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 20**Total no. authors:** 20**Corresponding author:** No

- 15** Javier Martin Broto. Advancing towards Better Cooperation for Better Sarcoma Prognoses. *Oncology*. 95 - 1, pp. 5 - 10. 12/2018. ISSN 0030-2414

**DOI:** 10.1159/000494860**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 1**Total no. authors:** 1**Corresponding author:** Yes**Impact source:** JCR**Category:** Science Edition - ONCOLOGY**Impact index in year of publication:** 2.278**Journal in the top 25%:** No**Source of citations:** JCR**Citations:** 3,93

- 16** R Alemany; DS Moura; A Redondo; J Martinez Trufero; S Calabuig; C Saus; A Obrador Hevia; R Ramos; VH Villar; C Valverde; MA Vaz; J Medina; I Felipe Abrio; Nadia Hindi; M Taron; Javier Martin Broto. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. *Clinical Cancer Research*. 24 - 21, pp. 5239 - 5249. 11/2018. ISSN 1078-0432

**DOI:** 10.1158/1078-0432.CCR-18-0851**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 16**Total no. authors:** 16**Corresponding author:** Yes**Impact source:** JCR**Category:** Science Edition - ONCOLOGY**Impact index in year of publication:** 8.911**Journal in the top 25%:** Yes**Source of citations:** JCR**Citations:** 78,17

- 17** X Garcia Del Muro; J Maurel; J Martinez Trufero; J Lavernia; A Lopez Pousa; R De Las Peñas; R Cubedo; JP Berros; A Casado Herráez; A De Juan; Javier Martin Broto. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. *Investigational New Drugs*. 36 - 3, pp. 468 - 475. 06/2018. ISSN 0167-6997  
**DOI:** 10.1007/s10637-018-0583-z  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 11  
**Total no. authors:** 11 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 51.873 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 3,91
- 18** Options for treating different soft tissue sarcoma subtypes. *Future Oncology*. 14 - 10s, pp. 25 - 49. 05/2018. ISSN 1479-6694  
**DOI:** 10.2217/fo-2018-0076  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 4  
**Total no. authors:** 5 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 2.279 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 4,05
- 19** S Pasquali; C Colombo; S Pizzamiglio; P Verderio; D Callegaro; S Stacchiotti; Javier Martin Broto; A Lopez Pousa; S Ferrari; A Poveda; A De Paoli; V Quagliuolo; JC Jurado; A Comandone; G Grignani; R De Sanctis; E Palassini; A Llomboat Bosch; AP Dei Tos; PG Casali; P Picci; A Gronchi. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. *European Journal of Oncology*. 93, pp. 29 - 36. 04/2018. ISSN 1128-6598  
**DOI:** 10.1016/j.ejca.2018.01.071  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 7  
**Total no. authors:** 22 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 2.709 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 73
- 20** Juan Martin Liberal; Antonio Lopez Pousa; Javier Martinez Trufero; Javier Martin Broto; Ricardo Cubedo; Javier Lavernia; Andrés Redondo; Jose Antonio Lopez Martín; Nuria Mulet Margalef; Xavier Sanjuan; Oscar M Tirado; Xavier Garcia Del Muro. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group of Research on Sarcomas (GEIS) Study. *Targeted Oncology*. 13 - 1, pp. 81 - 87. 02/2018. ISSN 1776-2596  
**DOI:** 10.1007/s11523-017-0539-9  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 4  
**Total no. authors:** 12 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 3.683  
**Source of citations:** JCR **Citations:** 1,14  
**Relevant results:** Q2

- 21** Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel; Vincenzi, Bruno; Fedenko, Alexander; Maki, Robert G; Somaiah, Neeta; Patel, Shreyaskumar; Brahmi, Mehedi; Blay, Jean Y; Boye, Kjetil; Sundby Hall, Kirsten; Gelderblom, Hans; Hindi, Nadia; Martin-Broto, Javier; Kosela, Hanna; Rutkowski, Piotr; Italiano, Antoine; Duffaud, Florence; Kobayashi, Eisuke; Casali, Paolo G; Provenzano, Salvatore; Kawai, Akira. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. *The oncologist*. 23 - 1, pp. 62 - 70. 01/2018. ISSN 1083-7159  
**DOI:** 10.1634/theoncologist.2017-0161  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 15  
**Total no. authors:** 23  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 5.252 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 11,83
- 22** Martin-Broto, J; Redondo, A; Valverde, C; Vaz, M A; Mora, J; Garcia Del Muro, X; Gutierrez, A; Tous, C; Carnero, A; Marcilla, D; Carranza, A; Sancho, P; Martinez-Trufero, J; Diaz-Beveridge, R; Cruz, J; Encinas, V; Taron, M; Moura, D S; Luna, P; Hindi, N; Lopez-Pousa, A. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). *Annals of oncology*. 28 - 12, pp. 2994 - 2999. 12/2017. ISSN 0923-7534  
**DOI:** 10.1093/annonc/mdx536  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 21 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 96.304 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 40,75
- 23** Redondo, Andres; Bague, Silvia; Bernabeu, Daniel; Ortiz-Cruz, Eduardo; Valverde, Claudia; Alvarez, Rosa; Martinez-Trufero, Javier; Lopez-Martin, Jose A.; Correa, Raquel; Cruz, Josefina; Lopez-Pousa, Antonio; Santos, Aurelio; Garcia del Muro, Xavier; Martin-Broto, Javier. Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). *Cancer Chemotherapy and Pharmacology*. 80 - 6, pp. 1113 - 1131. 12/2017. ISSN 0344-5704  
**DOI:** 10.1007/s00280-017-3436-0  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 14  
**Total no. authors:** 14 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - PHARMACOLOGY & PHARMACY  
**Impact index in year of publication:** 62.360 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 9,61
- 24** Joensuu, Heikki; Blay, Jean-Yves; Comandone, Alessandro; Martin-Broto, Javier; Fumagalli, Elena; Grignani, Giovanni; Del Muro, Xavier Garcia; Adenis, Antoine; Valverde, Claudia; Pousa, Antonio Lopez; Olivier, Bouche ; Italiano, Antoine; Bauer, Sebastian; Barone, Carlo; Weiss, Claudia; Crippa, Stefania; Camozzi, Maura; Castellana, Ramon; Le Cesne, Axel. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. *British Journal Of Cancer*. 117 - 9, pp. 1278 - 1285. 10/2017. ISSN 0007-0920  
**DOI:** 10.1038/bjc.2017.290  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 4  
**Total no. authors:** 19

**Impact source:** JCR

**Impact index in year of publication:** 5.922

**Source of citations:** JCR

**Category:** Science Edition - ONCOLOGY

**Journal in the top 25%:** Yes

**Citations:** 46,72

- 25** Jones, R. L.; Blay, J-Y.; Lecesne, A.; Martin-Broto, J.; Pontes, M. J.; Fernandez Santos, J. M.; Garcia San Andres, B.; Wang, G.; Wang, S.; Shin, C. R.; Maki, R.; Patel, S.; Demetri, G. D. S.A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas. ANNALS OF ONCOLOGY. 28, 09/2017. Available on-line at: <42nd European-Society-for-Medical-Oncology Congress (ESMO)>. ISSN 0923-7534

**Type of production:** Scientific paper

**Source of citations:** WOS

**Format:** Scientific and technical document or report

**Citations:** 0

- 26** Hindi, N.; Fernandez-Serra, A.; Martinez-Trufero, J.; Carranza-Carranza, A.; Lopez-Pousa, A.; Lavernia, J.; Arranz, J. L.; Alegret, R. Lopez; Martinez-Garcia, J.; Morales, C. Valverde; Cano, J. M.; Vaz, M. A.; Moura, D. S.; Bague, S.; Gonzalez-Campora, R.; Lopez-Guerrero, J. A.; Martin-Broto, J. Analysis of expression of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS). ANNALS OF ONCOLOGY. 28, 09/2017. Available on-line at: <42nd European-Society-for-Medical-Oncology Congress (ESMO)>. ISSN 0923-7534

**Type of production:** Scientific paper

**Format:** Scientific and technical document or report

- 27** Serrano, C.; Lopez Pousa, A.; Pajares, I.; Valverde Morales, C.; Duran, J.; Rubio-Casadevall, J.; Safont, M. J.; Martinez, V.; Diaz Beveridge, R.; Estival, A.; Vicente Baz, D.; Sebio Garcia, A.; Hindi, N.; Landolfi, S.; Olivares, D.; Garcia-Valverde, A.; Ledesma, P.; Arribas, J.; Carles Galceran, J.; Martin Broto, J. Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (> 5 years) to frontline imatinib (IM): A case-control study from GEIS. ANNALS OF ONCOLOGY. 28, 09/2017. Available on-line at: <42nd European-Society-for-Medical-Oncology Congress (ESMO)>. ISSN 0923-7534

**Type of production:** Scientific paper

**Source of citations:** WOS

**Format:** Scientific and technical document or report

**Citations:** 0

- 28** Mora, J.; Castaneda, A.; Perez-Jaume, S.; Lopez-Pousa, A.; Maradiegue, E.; Valverde, C.; Martin-Broto, J.; Garcia del Muro, X.; Cruz, O.; Cruz, J.; Martinez-Trufero, J.; Maurel, J.; Vaz, M. A.; de Alava, E.; de Torres, C. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). British Journal Of Cancer. 117 - 6, pp. 767 - 774. 09/2017. ISSN 0007-0920

**DOI:** 10.1038/bjc.2017.252

**Type of production:** Scientific paper

**Position of signature:** 7

**Total no. authors:** 15

**Impact source:** JCR

**Impact index in year of publication:** 5.416

**Source of citations:** JCR

**Format:** Journal

**Corresponding author:** No

**Category:** Science Edition - ONCOLOGY

**Journal in the top 25%:** Yes

**Citations:** 45,89

- 29** Casali, P. G.; Le Cesne, A.; Poveda, A.; Kotasek, D.; Rutkowski, P.; Hohenberger, P.; Fumagalli, E.; Judson, I.; Italiano, A.; Gelderblom, H.; Penel, N.; Kopp, H-G.; Goldstein, D.; Martin Broto, J.; Gronchi, A.; Wardelmann, E.; Marreaud, S.; Zalcborg, J.; Litiere, S.; Blay, J-Y. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. ANNALS OF ONCOLOGY. 28, 09/2017. ISSN 0923-7534

**Type of production:** Scientific paper

**Format:** Scientific and technical document or report

- 30** Francisco Bautista; Soledad Gallego; Adela Cañete; Jaume Mora; Cristina Díaz de Heredia; Ofelia Cruz; José María Fernández; Susana Rives; Pablo Berlanga; Raquel Hladun; Antonio Juan Ribelles; Luis Madero; Manuel Ramírez; Rafael Fernández Delgado; Antonio Pérez Martínez; Cristina Mata; Anna Llort; Javier Martín Broto; María Elena Cela; Gema Ramírez; Constantino Sábado; Tomás Acha; Itziar Astigarraga; Ana Sastre; Ascensión Muñoz; Mercedes Guibelalde; Lucas Moreno. [Early clinical trials in paediatric oncology in Spain: a nationwide perspective]. *Anales de pediatria*. 87 - 3, pp. 155 - 163. (Spain): 09/2017. ISSN 1695-4033  
**DOI:** 10.1016/j.anpedi.2016.07.007  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 18  
**Total no. authors:** 27  
**Impact source:** JCR **Category:** Science Edition - PEDIATRICS  
**Impact index in year of publication:** 1.318 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 1
- 31** Esther Martinez Font; Irene Felipe Abrio; Silvia Calabuig Fariñas; Rafael F Ramos; Josefa Terrasa; Oliver Vögler; Regina Alemany; Javier Martín Broto; Antònia Obrador Hevia. Disruption of TCF/ $\beta$ -catenin binding impairs Wnt signalling and induces apoptosis in soft tissue sarcoma cells. *Molecular cancer therapeutics*. 16 - 6, pp. 1166 - 1176. 06/2017. ISSN 1535-7163  
**DOI:** 10.1158/1535-7163.MCT-16-0585  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 8  
**Total no. authors:** 9 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 4.856 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 18,06
- 32** Javier Martín Broto; Peter Reichardt; Silvia Stacchiotti; Jean-Yves Blay. Review of past and present clinical cases with a view to future treatment options. *Future oncology*. 13 - 13s, pp. 11 - 28. 06/2017. ISSN 1479-6694  
**DOI:** 10.2217/fon-2017-0120  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 4 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 2.369 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 3,83
- 33** Javier Martín Broto; Virginia Martinez Marin; César Serrano; Nadia Hindi; José Antonio López Guerrero; Rafael Ramos Asensio; Ana Vallejo Benítez; David Marcilla Plaza; Ricardo González Cámpora. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. *Clinical and Translational Oncology*. 19 - 5, pp. 536 - 545. 05/2017. ISSN 1699-048X  
**DOI:** 10.1007/s12094-016-1581-2  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 9 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 2.392 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 2,33



- 34** Andrés Poveda; Xavier García Del Muro; Jose Antonio López Guerrero; Ricardo Cubedo; Virginia Martínez; Ignacio Romero; César Serrano; Claudia Valverde; Javier Martín Broto. GEIS guidelines for gastrointestinal sarcomas (GIST).Cancer treatment reviews. 55, pp. 107 - 119. 04/2017. ISSN 1532-1967  
**DOI:** 10.1016/j.ctrv.2016.11.011  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 9  
**Total no. authors:** 9 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 8.122 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 7.870
- 35** A. Gronchi; S. Stacchiotti; P. Verderio; S. Ferrari; J. Martin Broto; A. Lopez-Pousa; A. Llombart-Bosch; A.P. Dei Tos; P. Collini; J. Cruz Jurado; A. De Paoli; D.M. Donati; A. Poveda; V. Quagliuolo; A. Comandone; G. Grignani; C. Morosi; A. Messina; R. De Sanctis; S. Bottelli; E. Palassini; P.G. Casali; Piero Picci. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology. 27 - 12, pp. 1 - 5. Oxford University Press, 12/2016. ISSN 0923-7534  
**DOI:** 10.1093/annonc/mdw430  
**Type of production:** Scientific paper  
**Position of signature:** 5 **Corresponding author:** No  
**Total no. authors:** 23 **Category:** Science Edition - ONCOLOGY  
**Impact source:** JCR **Journal in the top 25%:** Yes  
**Impact index in year of publication:** 11.855 **Citations:** 34,42  
**Source of citations:** JCR
- 36** SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). Clinical and Translational Oncology. 18 - 12, pp. 1213 - 1220. 11/2016. ISSN 1699-048X  
**DOI:** 10.1007/s12094-016-1574-1  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 2 **Corresponding author:** No  
**Total no. authors:** 10 **Category:** Science Edition - ONCOLOGY  
**Impact source:** JCR  
**Impact index in year of publication:** 5.353 **Citations:** 2,08  
**Source of citations:** JCR
- 37** Marco Perez; Javier Peinado Serrano; Jose Manuel Garcia Heredia; Irene Felipe Abrio; Cristina Tous; Irene Ferrer; Javier Martin Broto; Carmen Saez; Amancio Carnero. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).Oncotarget. 7 - 41, pp. 67033 - 67046. 10/2016. ISSN 1949-2553  
**DOI:** 10.18632/oncotarget.11475  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 7 **Corresponding author:** No  
**Total no. authors:** 9 **Category:** Science Edition - ONCOLOGY  
**Impact source:** JCR **Journal in the top 25%:** Yes  
**Impact index in year of publication:** 5.168 **Citations:** 30,24  
**Source of citations:** JCR

- 38** Javier Martin-Broto; Antonio López Pousa; Ramón De las Peñas; Xavier García del Muro; Antonio Gutierrez; Javier Martinez-Trufero; Josefina Cruz; Rosa Alvarez; Ricardo Cubedo; Andrés Redondo; Joan Maurel; Juan A Carrasco; José A López- Martin; Ángeles Sala; Andrés Meana; Rafael Ramos; Jordi Martinez-Serra; José A Lopez-Guerrero; Isabel Sevilla; Carmen Balaña; Ángeles Vaz; Ana de Juan; Regina Alemany and Andrés Poveda. Randomized Phase II Study Of Trabectedin And Doxorubicin Compared With Doxorubicin Alone As First Line Treatment In Patients With Advanced Soft Tissue Sarcomas: A Spanish Group For Research On Sarcoma (GEIS) Study. REVISTA: JCO (IN PRESS). Journal Clinical Oncology. 34 - 19, pp. 2294 - 2302. 07/2016.  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 23 **Corresponding author:** Yes  
**Impact source:** ISI **Category:** Oncology (nursing)  
**Impact index in year of publication:** 18.443 **Journal in the top 25%:** Yes
- 39** J Martin-Broto; N. Hindi. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor. Current Opinion Oncology. 28 - 4, pp. 338 - 344. 07/2016. ISSN 1040-8746  
**DOI:** 10.1097/CCO.0000000000000302  
**Type of production:** Scientific paper  
**Position of signature:** 1  
**Total no. authors:** 2 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 3.414 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 2,96  
**Relevant results:** Q2
- 40** J Maurel; A López-Pousa; S Calabuig; S Bagué; XG Del Muro; X Sanjuan; J Rubió-Casadevall; M Cuatrecasas; J Martinez-Trufero; C Horndler; J Fra; C Valverde; A Redondo; A Poveda; I Sevilla; N Lainez; M Rubini; X García-Albéniz; J Martín-Broto; E de Alava. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clinical Sarcoma Research. 29 - 6, 06/2016.  
**DOI:** 10.1186/s13569-016-0050-6  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 19  
**Total no. authors:** 20 **Corresponding author:** No  
**Impact source:** ISI  
**Impact index in year of publication:** 2.11
- 41** VH Villar; O Vögler; F Barceló; J Martín-Broto; J Martínez-Serra; V Ruiz-Gutiérrez; R Alemany. Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. PLoS One. 24 - 11, 05/2016. ISSN 1932-6203  
**DOI:** 10.1371/journal.pone.0155946  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 4  
**Total no. authors:** 7 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - MATERIALS SCIENCE, MULTIDISCIPLINARY  
**Impact index in year of publication:** 3.057 **Journal in the top 25%:** Yes



- 42** Garcia Del Muro X; de Alava E; Artigas V; Bague S; Braña A; Cubedo R; Cruz J; Mulet-Margalef N; Narvaez JA; Martinez Tirado O; Valverde C; Verges R; Viñals J; Martin-Broto J. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). *Cancer Chemother Pharmacology*. 77 - 1, pp. 133 - 146. 01/2016. ISSN 0344-5704  
**DOI:** 10.1007/s00280-015-2809-5  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 14  
**Total no. authors:** 14 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - PHARMACOLOGY & PHARMACY  
**Impact index in year of publication:** 56.615 **Journal in the top 25%:** No  
**Source of citations:** JCR **Citations:** 9,39  
**Relevant results:** Q2
- 43** PG Casali; A Le Cesne; A Poveda Velasco; D Kotasek; P Rutkowski; P Hohenberger; E Fumagalli; IR Judson; A Italiano; H Gelderblom; A Adenis; JT Hartmann; F Duffaud; D Goldstein; JM Broto; A Gronchi; AP Dei Tos; S Marréaud; WT van der Graaf; JR Zalberg; S Litière; JY Blay. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas *JOURNAL/BOOK: J Clin Oncol. Journal of Clinical Oncology*. 33 - 36, pp. 4276 - 4283. 12/2015. ISSN 0732-183X  
**DOI:** 10.1200/JCO.2015.62.4304  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 15  
**Total no. authors:** 22 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 20.982 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 141,36  
**Relevant results:** 1ºDECIL
- 44** Palassini E; Ferrari S; Verderio P; De Paoli A; Martin Broto J; Quagliuolo V; Comandone A; Sangalli C; Palmerini E; Lopez-Pousa A; De Sanctis R; Bottelli S; Libertini M; Picci P; Casali PG; Gronchi A. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Espanol de Investigacion en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. *Journal Of Clinical Oncology*. 33 - 31, pp. 3628 - 3634. 11/2015. Available on-line at: <<http://europepmc.org/abstract/med/26351345>>. ISSN 0732-183X  
**DOI:** 10.1200/JCO.2015.62.9394  
**Type of production:** Scientific paper **Format:** Journal  
**Position of signature:** 5  
**Total no. authors:** 16 **Corresponding author:** No  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 20.982 **Journal in the top 25%:** Yes  
**Source of citations:** JCR **Citations:** 141,36
- 45** Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). *Annals of Surgical Oncology*. 22 - 9, pp. 2948 - 2957. 09/2015. ISSN 1068-9265



**DOI:** 10.1245/s10434-014-4360-8

**Type of production:** Scientific paper

**Position of signature:** 17

**Total no. authors:** 18

**Impact source:** JCR

**Impact index in year of publication:** 92.250

**Source of citations:** JCR

**Format:** Journal

**Corresponding author:** No

**Category:** Science Edition - SURGERY

**Journal in the top 25%:** Yes

**Citations:** 20,83

- 46** H Joensuu; J Martín-Broto; T Nishida; P Reichardt; P Schöffski; RG. Maki. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. *European Journal Of Cancer*. 51 - 12, pp. 1611 - 1617. 08/2015. ISSN 0959-8049

**DOI:** 10.1016/j.ejca.2015.05.009

**Type of production:** Scientific paper

**Position of signature:** 2

**Total no. authors:** 6

**Impact source:** JCR

**Impact index in year of publication:** 6.163

**Source of citations:** JCR

**Format:** Journal

**Corresponding author:** Yes

**Category:** Science Edition - ONCOLOGY

**Journal in the top 25%:** Yes

**Citations:** 25.368

- 47** Obrador-Hevia A; Martínez-Font E; Felipe-Abrio I; Calabuig-Fariñas S; Serra-Sitjar M; López-Guerrero JA; Ramos R; Alemany R; Martín-Broto J. RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas. *Cancer Investigation*. 33 - 9, pp. 440 - 450. 08/2015. Available on-line at: <<http://europepmc.org/abstract/med/26279182>>. ISSN 0735-7907

**DOI:** 10.3109/07357907.2015

**Type of production:** Scientific paper

**Position of signature:** 9

**Total no. authors:** 9

**Impact source:** JCR

**Impact index in year of publication:** 2.231

**Source of citations:** JCR

**Format:** Journal

**Corresponding author:** No

**Category:** Science Edition - ONCOLOGY

**Journal in the top 25%:** No

**Citations:** 2,63

**Relevant results:** Q3

- 48** Maki RG; Blay JY; Demetri GD; Fletcher JA; Joensuu H; Martín-Broto J; Nishida T; Reichardt P; Schöffski P; Trent JC. Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. *Oncologist*. 20 - 7, pp. 823 - 830. 07/2015. Available on-line at: <<http://europepmc.org/abstract/med/26070915>>. ISSN 1083-7159

**DOI:** 10.1634/theoncologist.2014-0471

**Type of production:** Scientific paper

**Position of signature:** 6

**Total no. authors:** 10

**Impact source:** JCR

**Impact index in year of publication:** 4.789

**Source of citations:** JCR

**Format:** Journal

**Corresponding author:** No

**Category:** Science Edition - ONCOLOGY

**Journal in the top 25%:** Yes

**Citations:** 8,96

- 49** A López-Pousa; JM Broto; T Garrido; J Vázquez. Giant cell tumour of bone: new treatments in development. *Clinical and Translational Oncology*. 17 - 6, pp. 419 - 430. 06/2015. ISSN 1699-048X

**DOI:** 10.1007/s12094-014-1268-5



**Type of production:** Scientific paper  
**Position of signature:** 2  
**Total no. authors:** 4  
**Impact source:** JCR  
**Impact index in year of publication:** 2.075  
**Source of citations:** JCR

**Format:** Journal  
**Corresponding author:** No  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** No  
**Citations:** 2,02

- 50** Grignani G; Martín-Broto J; Schuler M; Reichardt P. Trabectedin clinical cases: use according to indication in diverse clinical scenarios. *Future Oncology*. 11 - 11, pp. 15 - 24. 06/2015. Available on-line at: <<http://europepmc.org/abstract/med/26043311>>. ISSN 1479-6694

**DOI:** 10.2217/fon.15.76

**Type of production:** Scientific paper  
**Position of signature:** 2  
**Total no. authors:** 4  
**Impact source:** JCR  
**Impact index in year of publication:** 2.129  
**Source of citations:** JCR

**Format:** Journal  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** No  
**Citations:** 2,79

**Relevant results:** Q3

- 51** Márquez-Rodas I; Martín González M; Nagore E; Gómez-Fernández C; Avilés-Izquierdo JA; Maldonado-Seral C; Soriano V; Majem-Tarruella M; Palomar V; Maseda R; Martín-Carnicero A; Puertolas T; Godoy E; Cerezuela P; Ochoa de Olza M; Campos B; Perez-Ruiz E; Soria A; Gil-Arnaiz I; Gonzalez-Cao M; Galvez E; Arance A; Belon J; de la Cruz-Merino L; Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM). Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study. *PloS One*. 10 - 4, 04/2015. Available on-line at: <<http://europepmc.org/abstract/med/25874698>>. ISSN 1932-6203

**DOI:** 10.1371/journal.pone.0124239

**Type of production:** Scientific paper  
**Position of signature:** 26  
**Total no. authors:** 26  
**Impact source:** JCR  
**Impact index in year of publication:** 3.057  
**Source of citations:** Bioxbio JI

**Format:** Journal  
**Corresponding author:** No  
**Category:** Science Edition - MATERIALS SCIENCE, MULTIDISCIPLINARY  
**Journal in the top 25%:** Yes  
**Citations:** 425.015

**Relevant results:** Q1

**Relevant publication:** No

- 52** Stacchiotti S and Sommer J Stacchiotti S and Sommer; M Uhl; D Vanel; C Vleggeert-Lankamp; S Scheipl; OJ Norum; W Peul; N Nicolai; P Rutkowski; C Morosi; E Tamborini; J Martín-Broto; S Radaelli; A Leithner; V Torri; M Krengli; S Pilotti; H Keulen; B Kasper; L Jeys; F Hornicek; P Hohenberger; R Haas; A Gronchi; R Grimer; H Gelderblom; S Froelich; P Fossati; A Flanagan; F Doglietto; TF DeLaney; J Debus; PG Casali; R Capanna; S Boriani; S Bollè; JY Blay; C Ares; on behalf of a Chordoma global consensus group\*. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncology*. 16 - 2, pp. e71 - 83. 02/2015. ISSN 1470-2045

**DOI:** 10.1016/S1470-2045(14)71190-8

**Type of production:** Scientific paper  
**Position of signature:** 26  
**Total no. authors:** 39  
**Impact source:** JCR  
**Impact index in year of publication:** 26.509

**Format:** Journal  
**Corresponding author:** No  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** Yes



**Source of citations:** JCR

**Citations:** 30,8

**Relevant results:** 1ºDECIL

- 53** Martin- Broto J. Indirect comparisons in cost-effectiveness analysis: are we being naïve?. Clinical and translational oncology. 17 - 1, pp. 85 - 86. 01/2015. ISSN 1699-048X  
**DOI:** 10.1007/s12094-014-1256-9  
**Type of production:** Scientific paper  
**Position of signature:** 1  
**Total no. authors:** 1  
**Impact source:** JCR  
**Impact index in year of publication:** 2.020  
**Source of citations:** JCR  
**Relevant results:** Q3  
**Corresponding author:** Yes  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** No  
**Citations:** 1,74
- 54** Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. Annals of Oncology. 23 - 7, 09/2014.  
**Type of production:** Scientific paper  
**Position of signature:** 26  
**Total no. authors:** 54  
**Impact source:** JCR  
**Impact index in year of publication:** 7.040  
**Corresponding author:** No  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** Yes
- 55** Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 25 - 3, pp. 21 - 26. 09/2014. ISSN 0923-7534  
**DOI:** 10.1093/annonc/mdu255  
**Type of production:** Scientific paper  
**Position of signature:** 26  
**Total no. authors:** 41  
**Impact source:** JCR  
**Impact index in year of publication:** 7.040  
**Source of citations:** JCR  
**Relevant results:** Q1  
**Corresponding author:** No  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** Yes  
**Citations:** 26.807
- 56** Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 25 - 3, 09/2014.  
**Type of production:** Scientific paper  
**Position of signature:** 26  
**Total no. authors:** 49  
**Impact source:** JCR  
**Impact index in year of publication:** 7.040  
**Corresponding author:** No  
**Category:** Science Edition - ONCOLOGY  
**Journal in the top 25%:** Yes
- 57** Martin-Broto J; Cleeland CS; Glare PA; Engellau J; Skubitz KM; Blum RH; Ganjoo KN; Staddon A; Dominkus M; Feng A; Qian Y; Braun A; Jacobs I; Chung K; Atchison C. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. Acta Oncol. 53(9) - 1173-9. IF: (3.71, 2014).  
**Type of production:** Scientific paper



- 58** Martin-Broto J; Gutierrez AM; Ramos RF; Lopez-Guerrero JA; Ferrari S; Stacchiotti S; Picci P; Calabuig S; Collini P; Gambarotti M; Bague S; Dei Tos AP; Palassini E; Luna P; Cruz J; Cubedo R; Martinez-Trufero J; Poveda A; Casali PG; Fernandez-Serra A; Lopez-Pousa A; Gronchi A.MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study.Mol Cancer Ther.13 (1) PÁG.INICIAL - FINAL: 249-59 IF, 2014.  
**Type of production:** Scientific paper
- 59** Villar VH; Vögler O; Barceló F; Gómez-Florit M; Martínez-Serra J; Obrador-Hevia A; Martín-Broto J; Ruiz-Gutiérrez V; Alemany R.Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.J Nutr Biochem. 25(4) PÁG.INICIAL - FINAL: 429-38 IF, 2014.  
**Type of production:** Scientific paper
- 60** Martín-Liberal J; López-Pousa A; Broto JM; Cubedo R; Gallego O; Brendel E; Tirado OM; Del Muro XG.Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.Invest New Drugs. 32(2) PÁG.INICIAL - FINAL: 287-94 IF, 2014.  
**Type of production:** Scientific paper
- 61** A. Gronchi; P. Verderio; A. De Paoli; A. Ferraro; O. Tendero; J. Majò; J. Martin; A. Comandone; G. Grignani; S. Pizzamiglio; V. Quagliuolo; P. Picci; S. Frustaci; A. P. Dei Tos; E. Palassini; S. Stacchiotti; S. Ferrari; M. Fiore P. G. Casali.Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas. Annals of Oncology. 24(3) PÁG.INICIAL - FINAL: 817-23 I, 2013.  
**Type of production:** Scientific paper
- 62** Reichardt; P.; J. Y. Blay; I. Boukovinas; T. Brodowicz; J. M. Broto; P. G. Casali; M. Decatris; M. Eriksson; H. Gelderblom; P. Kosmidis; A. Le Cesne; A. L. Pousa; M. Schlemmer; J. Verweij; and H. Joensuu.Adjuvant Therapy in Primary Gist: State-of-the-Art.Annals of Oncology. 23(11) PÁG.INICIAL - FINAL: 2776-81 I, 2012.  
**Type of production:** Scientific paper
- 63** Villar VH; Vögler O; Martínez-Serra J; Ramos R; Calabuig-Fariñas S; Gutiérrez A; Barceló F; Martín-Broto J; Alemany R.Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.PLoS One.7(5): PÁG.INICIAL - FINAL: e37735 IF, 2012.  
**Type of production:** Scientific paper
- 64** Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P. European Organisation for Research and Treatment of Cancer.Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.Clin Cancer Res.18(16) PÁG.INICIAL - FINAL: 4458-64 I, 2012.  
**Type of production:** Scientific paper
- 65** Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger; on behalf of the EORTC Soft Tissue and Bone Sarcoma Group and the PALETTE study group. (Co-author in. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet.379(9829) PÁG.INICIAL - FINAL: 1879-86., 2012.  
**Type of production:** Scientific paper
- 66** García del Muro Solans X; Martín Broto J; Lianes Barragán P; Cubedo Cervera R. SEOM (Spanish Society of Clinical Oncology).SEOM clinical guidelines for the management of adult soft tissue sarcomas. Clin Transl Oncol. 14(7) PÁG.INICIAL - FINAL: :541-4 IF;., 2012.  
**Type of production:** Scientific paper



- 67** Poveda; A.; F. Rivera; and J. Martin. Seom Guidelines for Gastrointestinal Stromal Sarcomas (Gist). Clin Transl Oncol. 14(7): PÁG.INICIAL - FINAL: 536-40. I, 2012.  
**Type of production:** Scientific paper
- 68** Alessandro Gronchi; Sergio Frustaci; Mario Mercuri; Javier Martin; Antonio Lopez-Pousa; Paolo Verderio; Lidia Mariani; Pinuccia Valagussa; Rosalba Miceli; Silvia Stacchiotti; Angelo Paolo Dei Tos; Antonino De Paoli; Alessandra Longhi; Andres Poveda; Vittorio Quagliuolo; Alessandro Comandone; Paolo Giovanni Casali; and Piero Picci. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial from the Italian Sarcoma Group and the Spanish. Journal of Clinical Oncology. 30, PÁG.INICIAL - FINAL: 850-856 IF, 2012.  
**Type of production:** Scientific paper
- 69** Stacchiotti S; Verderio P; Messina A; Morosi C; Collini P; Llombart-Bosch A; Martin J; Comandone A; Cruz J; Ferraro A; Grignani G; Pizzamiglio S; Quagliuolo V; Picci P; Frustaci S; Dei Tos AP; Casali PG; Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 118(23) PÁG.INICIAL - FINAL: 5857-66 I, 2012.  
**Type of production:** Scientific paper
- 70** Xavier García-del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gomez-España; Joaquín Fra; Josefina Cruz; Andre´s Poveda; Andre´s Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andre´s; and Jose´ M. Buesa. Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. J Clin Oncol. 29(18) PÁG.INICIAL - FINAL: 2528-33., 2011.  
**Type of production:** Scientific paper
- 71** García Del Muro X, Martín J, Maurel J, Cubedo R, Bagué S, de Álava E, Pousa AL, Narváez JA, Ortiz E.; Grupo Español de Investigación en Sarcomas (GEIS). Soft tissue sarcomas: clinical practice guidelines. Med Clin (Barc). 136(9) PÁG.INICIAL - FINAL: 408.e1-8, 2011.  
**Type of production:** Scientific paper
- 72** Martínez-Serra J; Maffiotte E; Martín J; Bex T; Navarro-Palou M; Ros T; Plazas JM; Vögler O; Gutiérrez A; Amat JC; Ramos R; Saus C; Ginés J; Alemany R; Diaz M; Besalduch. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action. J. Eur J Pharmacol. 658(2 - 3): PÁG.INICIAL/FI, 2011.  
**Type of production:** Scientific paper
- 73** Javier Martín-Broto; Luis Rubio; Regina Alemany; Silvia Calabuig; Julia Cruz-Mojarrieta and José Antonio López-Guerrero. Clinical Implications of KIT and PDGFRA in Gastrointestinal Stromal Tumors. Clin Transl Oncol. 12(10) PÁG.INICIAL - FINAL: 670-6. IF, 2010.  
**Type of production:** Scientific paper
- 74** Martín-Broto J; Gutierrez A; Garcia-del-Muro X; Lopez-Guerrero JA; Martinez-Trufero J; de Sande LM; Lainez N; Maurel J; De Juan A; Losa F; Andres R; Casado A; Tejido PG; Blanco R; Carles J; Bellmunt J; Gomez-España A; Ramos R; Martinez-Serra J; Llombart-Bosch A; Poveda A. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 21(7) PÁG.INICIAL - FINAL: 1552-7 IF, 2010.  
**Type of production:** Scientific paper
- 75** Gutiérrez A; Martínez-Serra J; Barceló B; Sampol A; Viñas L; González G; Bea MD; Amat JC; Martín J; Ramos R; Bautista A; Forteza-Rey J; Rodríguez J; Besalduch J. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted. Int J Lab Hematol. 32(6 Pt 2) PÁG.INICIAL - FINAL: 582-9 IF, 2010.



**Type of production:** Scientific paper

- 76** A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group; the Italian Sarcoma Group; the NCRI Sarcoma Clinical Studies Group (UK); the Japanese Study Group on GIST; the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Gronchi A; Judson I; Nishida T; Poveda A; Martin J; Reichardt P; Casali PG; Cesne AL; Hohenberger P; Blay JY. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? REF. Eur J Cancer. 45(7) PÁG. INICIAL - FINAL: 1103-6. I, 2009.

**Type of production:** Scientific paper

- 77** Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. EF. Lancet Oncol. 10(11) PÁG. INICIAL - FINAL: 1045-52 I, 2009.

**Type of production:** Scientific paper

- 78** Maurel J; Lopez-Pousa A; de las Penas R; Fra J; Martin J; Cruz J; Casado A; Poveda A; Martinez-Trufero J; Balana C; Gomez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubio J; Andres R; Sevilla I; de la Cruz JJ; del Muro XG; Buesa JM. Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. REF. J Clin Oncol. 27(11) PÁG. INICIAL - FINAL: 1893-8. I, 2009.

**Type of production:** Scientific paper

- 79** BIG 1-98 Collaborative Group; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS. (Co-author in the author list of BIG collaborative group). Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer REF. The New England Journal of Medicine. 361; 8: PÁG. INICI - FINAL: 766- 776., 2009.

**Type of production:** Scientific paper

- 80** Jerzy Lasota; Christopher L Corless; Michael C Heinrich; Maria Debiec- Rychter; Raf Sciot; Eva Wardelmann; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Sonja E Steigen; Jerzy Stachura; Agnieszka Wozniak; Cristina Antonescu; Ondrej Daum; Javier Martin; Javier Garcia del Muro and Markku Miettinen. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases Revista: Modern Pathology (Q1). pp. 476 - 484. 2008.

**Type of production:** Scientific paper

**Impact source:** SCOPUS

**Impact index in year of publication:** 4.670

- 81** A López-Pousa; R Losa; J Martín; J Maurel; J Fra; M Sierra; A Casado; J García del Muro; A Poveda; C Balaña; J Martínez-Trufero; E Esteban and J M Buesa. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study Revista: British Journal of Cancer (Q1). British Journal of Cancer. 94, pp. 1797 - 1802. 2006.

**Type of production:** Scientific paper

**Impact source:** SCOPUS

**Impact index in year of publication:** 4.346

- 82** López-Pousa A; Martín J; Montalar J; de las Peñas R; García del Muro X; García del Muro X; Cruz J; Maurel J; Escudero P; Casado A; Buesa JM; Martínez-Trufero J; Bover I; Sevilla I; Balaña C; Paredes A; Carles J; Vicent J; Cassinello J.; Cruz J; Maurel J; Escudero P; Casado A; Buesa JM; Martínez-Trufero J.; Bover I; Sevilla I; Balaña C; Paredes A; Carles J; Vicent J; Cassinello J. Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Revista: Sarcoma. Sarcoma. 2006, pp. 1 - 8. 2006.

**Type of production:** Scientific paper



- 83** Carles Galcerán J; Bastus Piulats R; Martín-Broto J; Maroto Rey P; Nogué 11 Aligué M; Domenech Santasusana M; Arcusa Lanza A; Bellmunt Molins J; Colin C; Girard A.A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Revista: Clin Transl Oncol.Clin Transl Oncol.7, pp. 66 / - 73. 2005.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS
- 84** García del Muro X; López-Pousa A; Martín J; Buesa JM; Martínez-Trufero J; Casado A; Poveda A; Cruz J; Bover I; Maurel J. A. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study Revista: Cancer (Q1). Sarcoma. 104, pp. 1706 / - 1712. 2005.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 4.582
- 85** Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro X; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez-Trufero J; de Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM.Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). Revista: Journal of Clinical Oncology (Q1). Journal of Clinical Oncology. 23, pp. 6190 - 6198. 2005.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 17.793
- 86** Poveda A; López-Pousa A; Martín J; García del MuroX; Bernabé R; Casado A; Balañá C; Sanmartín O; Menéndez MD; Escudero P; Cruz J; Belyakova E; Menéndez D; Buesa JM.Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx®) / Doxil® and quality of life evaluation (EORTC QLQC30) in adult patients with advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS). Revista: Sarcoma. Sarcoma. 9, pp. 127 / - 132. 2005.  
**Type of production:** Scientific paper
- 87** (por orden de autoría): Balañá C; López-Pousa A; Berrocal A; Yaya-Tur R; Herrero A; García JL; Martín-Broto J; Benavides M; Cerdá-Nicolás M; Ballester R; Balart J; Capellades J.Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro- Oncology Group (GENOM). Revista: J Neurooncol.J Neurooncol. 70, pp. 359 / - 369. 2004.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 2.752
- 88** Maurel J; Buesa JM; López-Pousa A; García del Muro X; Quintana MJ; Martín J; Casado A; Martínez-Trufero J; de las Peñas R; Balañá C.Salvage surgical resection after high-dose ifosfamide (hdif) based regimens in advanced soft tissue sarcoma (asts): a potential positive selection bias – a study of Spanish group for research on sarcomas (GEIS). Revista: Journal of Surgical Oncology (Q3). Journal of Surgical Oncology. 88, pp. 44 / - 49. 2004.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 2.5

- 89** Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martí; Spanish Group for Research on Sarcomas (GEIS). Título / Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Revista: Cancer (Q1). Cancer. 100, pp. 1498 - 1506. 2004.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 4.582
- 90** Buesa JM; Fra J; Antón A; López-Pousa A; Martín J; García del Muro X; Escudero P; Casado A; Poveda A. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS). Revista: Annals of Oncology (Q1) 12. Annals of Oncology. 9, pp. 783 - 785. 1998.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 5.647
- 91** MJ. Rebassa Lluell; C. Gutierrez Sanz-Gadea; J. Martín-Broto; A. Mus Malleu; F. Hidalgo Pardo; D. Muñoz Velez; V. Riera Marí; R. Ramos Asensio; M. Ozonas Moragues. Leiomiosarcoma de cava inferior. A propósito de un caso. Revista: Actas Urol Esp. 22(5): 438-442. 1998. Actas Urol Esp. 22, pp. 438 - 442. 1998.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 5.647
- 92** Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro X; Bellmunt J; Arranz F; Valenti V; Escudero P; Menéndez D; Casado A; Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Revista: Annals of Oncology (Q1). Annals of Oncology. 9, pp. 871 - 876. 1998.  
**Type of production:** Scientific paper  
**Impact source:** SCOPUS  
**Impact index in year of publication:** 5.647
- 93** PG Casali; A Le Cesne; A Poveda Velasco; D Kotasek; P Rutkowski; P Hohenberger; E Fumagalli; IR Judson; A Italiano; H Gelderblom; A Adenis; JT Hartmann; F Duffaud; D Goldstein; JM Broto; A Gronchi; AP Dei Tos; S MARRÉAUD; WT van der Graaf; JR Zalcborg; S Litière; JY. Blay. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 33 - 36, pp. 4276 - 4283.  
**Type of production:** Scientific paper
- 94** J Martin Broto; L Montaner; VM Encinas; O Tendero. Biopsia. Tratado de Sarcomas de Partes Blandas. 2015.  
**Type of production:** Book chapter
- 95** Javier Martin Broto; Irene Felipe Abrio; Pilar Sancho. Sarcomas with actionable mutations. pp. 1 - 11. P. Permanyer, 2015.  
**Type of production:** Book chapter **Format:** Book
- 96** J Martin Broto; R Ramos; I Felipe-Abrio; López-Guerrero. Tratado de Sarcomas de Partes Blandas. Subtipos translocación específica. 2015.  
**Type of production:** Book chapter **Format:** Book



- 97** A Lopez-Pousa; J Martin Broto. Tratamiento sistémico de la enfermedad localizada. Tratado de Sarcomas de Partes Blandas :. 2015.  
**Type of production:** Book chapter **Format:** Book
- 98** Reichardt P; Leahy M; Garcia Del Muro X; Ferrari S; Martin J; Gelderblom H; Wang J; Krishna A; Eriksson J; Staddon A; Blay JY. Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. 10.1155/2012/740279.Sarcoma.2012:740279. PÁG.I - FINAL: IF: DOI (, 2012).  
**Type of production:** Book chapter
- 99** Javier Martín Broto; Antonia Perelló Martorell; Joan Maurel Santasusana; Rafael Ramos Asensio; Óscar Tendero Gómez. Sarcomas de partes blandas REF.Tratado de Oncología.2. PÁG.INICIAL - FINAL: 273 - 307., Publicaciones Permanyer, 2009. ISBN 978-84-92620-18-0  
**Type of production:** Book chapter
- 100** Javier Martín Broto y Antonio Gutiérrez13. Capítulo IV: Factores pronósticos en tumores de estroma gastrointestinal Libro: GIST (Patologías Nicho). pp. 59 - / final: 72. MadridCLYOU & US, S.A., 2008. ISBN 978-84-690-6301-9  
**Legal deposit:** M-56189-2008  
**Type of production:** Book chapter
- 101** Javier Martin Broto; J Cruz; Claudia Valverde; Ricardo Cubedo. Tratado de Sarcomas de partes Blandas. pp. 382. Nature Publishing Group Iberoamerica, S.L., 2015.  
**Type of production:** Scientific book or monograph **Format:** Book
- 102** A. López Pousa; J. Majó; J. Martín. Sarcomas óseos y neuroectodérmicos del adulto. Oncología Médica. 2, pp. 1061 - / final: 1093. MadridGrupo Aula Médica, S.A., 1999. ISBN 84-7885-209-3  
**Type of production:** Scientific book or monograph **Format:** Book
- 103** Javier Martin Broto; Nadia Hindi. In Reply. Oncologist. 24 - 6, pp. e401 - e402. 06/2019. ISSN 1083-7159  
**DOI:** 10.1634/theoncologist.2019-0052  
**Type of production:** Review **Format:** Journal  
**Position of signature:** 1  
**Total no. authors:** 2 **Corresponding author:** Yes  
**Impact source:** JCR **Category:** Science Edition - ONCOLOGY  
**Impact index in year of publication:** 5.252 **Journal in the top 25%:** Yes
- 104** Javier Martín-Broto. Goal 3: Controlling Tumor Growth and Preserving Quality of Life. Cancer & Chemotherapy Reviews. 11 - Supplement, pp. 13 - 16. Permanyer, 07/2016.  
**Type of production:** Review
- 105** Javier Martín Broto; Axel Le Cesne; Peter Reichardt. The importance of treating by histological subtype in advanced soft tissue sarcoma. Future Oncology. 13 - Supplement 1, pp. 23 - 31. Future science group, 01/2017.  
**Type of production:** Symposium Paper  
**Position of signature:** 1  
**Total no. authors:** 3 **Corresponding author:** No
- 106** A. Poveda; V. Martinez; C. Serrano; I. Sevilla; M.J. Lecumberri; R.D. de Beveridge; A. Estival; D. Vicente; J. Rubió; J. Martin-Broto. SEOM-Spanish Cancer Research Cooperative Groups' clinical guideline for gastrointestinal sarcomas (GIST) (2016). Clinical Translational Oncology. Springer, 2016.  
**Type of production:** Clinical Guidelines in Oncology

**Corresponding author:** Yes

- 107** Leo Kager; Jeremy Whelan; Uta Dirksen; Bass Hassan; Jakob Anninga; Lindsey Bennister; Judith V. M. G. Bovée; Bernadette Brennan; Javier M. Broto; Laurence Brugières; Anne\_Marie Cleton?Jansen; Christopher Copland; Aurélie Dutour; Franca Fagioli; Stefano Ferrari; Marta Fiocco; Emmy Fleuren; Nathalie Gaspar; Hans Gelderblom; Craig Gerrand; Joachim Gerß; Ornella Gonzato; Winette van der Graaf; Stefanie Hecker?Nolting; David Herrero? Martín; Stephanie Klco?Brosius; Heinrich Kovar; Ruth Ladenstein; Carlo Lancia; Marie-Cecile LeDeley; Martin G. McCabe; Markus Metzler; Ola Myklebost; Michaela Nathrath; Piero Picci; Jenny Potratz; Françoise Redini; Günther H.S. Richter; Denise Reinke; Piotr Rutkowski; Katia Scotlandi; Sandra Strauss; David Thomas; Oscar M. Tirado; Franck Tirode; Gilles Vassal; Stefan S. Bielack. The ENCCA?WP7/EuroSarc/EEC/ PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report. Clinical Sarcoma Research. 6 - 3, pp. 1 - 9. BioMed Central, 2016.

**Type of production:** Meeting Report

**Corresponding author:** No

- 108** A Poveda; XG del Muro; JA López-Guerrero; V Martínez; I Romero; C Valverde; R Cubedo; J Martín-Broto. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).Cancer Chemother Pharmacol.74(5); pp. 883 - 898. 11/2014.

**Type of production:** guidelines

- 109** ESMO / European Sarcoma Network Working Group.Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol.23 Suppl 7, pp. vii100 - 9. 2012.

- 110** ESMO / European Sarcoma Network Working Group.Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol.23 Suppl 7, pp. vii49 - 55. 2012.

- 111** ESMO / European Sarcoma Network Working Group.Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol.23 Suppl 7, pp. :vii92 - 9. 2012.

- 112** P. G. Casali; L. Jost; S. Sleijfer; J. Verweij; J.-Y. Blay and On behalf of the ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Revista: Annals of Oncology (Q1). 19, pp. 89 - 9310. 2008.

**Impact source:** SCOPUS

**Impact index in year of publication:** 5.647

### Works submitted to national or international conferences

- 1** **Title of the work:** Efficacy of Bortezomib in Sarcomas with high levels of MAP17 (PDZK1IP1)

**Name of the conference:** CTOS - 2016 Annual Meeting

**Corresponding author:** No

**City of event:** Lisbon, Portugal

**Date of event:** 09/11/2016

**End date:** 12/11/2016

**Organising entity:** CTOS

Amancio Carnero; Marco Perez; Javier Peinado Serrano; Jose Manuel Garcia Heredia; Irene Felipe Abrio; Cristina Tous; Irene Ferrer; Javier Martin Broto; Carmen Saez.



- 2** **Title of the work:** Efficacy of Bortezomib in Sarcomas with high levels of MAP17 (PDZK1IP1)  
**Name of the conference:** CTOS - 2016 Annual Meeting  
**Corresponding author:** No  
**City of event:** Lisbon,  
**Date of event:** 09/11/2016  
**End date:** 12/11/2016  
**Organising entity:** CTOS  
Amancio Carnero; Marco Perez; Javier Peinado; Jose Manuel Garcia Heredia; Irene Felipe; Cristina Tous; Irene Ferrer; Javier Martin Broto; Carmen Saez.
- 3** **Title of the work:** Exploratory analysis of immunomodulation and apoptosis factors in alveolar soft-part sarcoma: A retrospective study from the spanish group for research on sarcoma (GEIS)  
**Name of the conference:** CTOS - 2016 Annual Meeting  
**Corresponding author:** No  
**City of event:** Lisbon, Portugal  
**Date of event:** 09/11/2016  
**End date:** 12/11/2016  
**Organising entity:** CTOS  
Nadia Hindi; Javier Martinez Trufero; Andres Carranza; Antonio Lopez Pousa; Ramiro Alvarez; Juan Luis Arranz; Jeronimo Martinez; Claudia Valverde; Juana Maria Cano; Cristina Tous; Romina Ribas; Ricardo Gonzalez Campora; Javier Martin Broto.
- 4** **Title of the work:** Exploratory analysis of immunomodulation and apoptosis factors in alveolar soft-part sarcoma: A retrospective study from the spanish group for research on sarcoma (GEIS)  
**Name of the conference:** CTOS - 2016 Annual Meeting  
**Corresponding author:** No  
**City of event:** Lisbon,  
**Date of event:** 09/11/2016  
**End date:** 12/11/2016  
**Organising entity:** CTOS  
NADIA HINDI; JAVIER MARTIN TRUFERO; ANDRES CARRANZA; ANTONIO LOPEZ POUSA; RAMIRO ALVAREZ; JUAN LUIS ARRANZ; JERONIMO MARTINEZ; CLAUDIA VALVERDE; JUANA MARIA CANO; CRISTINA TOUS; ROMINA RIBAS; RICARDO GONZALEZ CAMPORA; JAVIER MARTIN BROTO.
- 5** **Title of the work:** Initial Reports of Euro Ewing 2012 and REECUR - International randomised controlled trials of chemotherapy for newly diagnosed and recurrent/ refractory Ewing Sarcomas (ES)  
**Name of the conference:** CTOS - 2016 Annual Meeting  
**Corresponding author:** No  
**City of event:** Lisbon, Portugal  
**Date of event:** 09/11/2016  
**End date:** 12/11/2016  
**Organising entity:** CTOS  
Bernardette Brennan; Martin McCabe; Veronica Moroz; Uta T. Dirksen; Nathalie Gaspar; Perrine Marec Bérard; Javier Martin; Kirsten Sundby Hall; Jukka Jukka Kanerva; Hans Gelderblom; Stefano Ferrari; Sandra Strauss; Jeremy Whelan; Keith Wheatley.
- 6** **Title of the work:** Pediatric-type rhabdomyosarcoma in adults: A retrospective analysis from the spanish group for research on sarcomas (GEIS)  
**Name of the conference:** CTOS - 2016 Annual Meeting  
**Corresponding author:** No  
**City of event:** Lisbon, Portugal  
**Date of event:** 09/11/2016



**End date:** 12/11/2016

**Organising entity:** CTOS

Nadia Hindi; Pablo Luna; Antonio Lopez Pousa; Jordi Rubio; Claudia Valverde; Javier Martinez Trufero; Jeronimo Martinez; Maria Angeles Sala; Juan Luis Arranz; Fatima Toscano; Rosa Alvarez; Juana Maria Cano; Nuria Lainez; Ana de Juan; Javier Martin Broto.

- 7** **Title of the work:** Platinum-based regimens in advanced pediatric type rhabdomyosarcoma in adults: experience of two centers

**Name of the conference:** CTOS - 2016 Annual Meeting

**Corresponding author:** No

**City of event:** Lisbon, Portugal

**Date of event:** 09/11/2016

**End date:** 12/11/2016

**Organising entity:** CTOS

Nadia Hindi; Pablo Luna; Jose Duran; Pilar Sancho; Roberto Lasso; Alvaro Montaña; Rafael Ramos; Javier Martin Broto.

- 8** **Title of the work:** Prognostic significance of WNT signaling pathway molecules in non-gastric localized GIST patients. A tissue microarray-based (TMA) analysis. A spanish group for research on sarcoma (GEIS) study

**Name of the conference:** CTOS - 2016 Annual Meeting

**Corresponding author:** Yes

**City of event:** Lisbon, Portugal

**Date of event:** 09/11/2016

**End date:** 12/11/2016

**Organising entity:** CTOS

Javier Martin Broto; Marta Mendiola; Laura Guerra; Antonio Gutierrez; Irene Felipe; Javier Martinez Trufero; Luis Miguel de Sande Gonzalez; Nadia Hindi; Cristina Tous; Claudia Valverde; Antonio Casado; Rafael Ramos; Virginia Martinez Marin.

- 9** **Title of the work:** Timelines associated with opening two clinical trials (Euro Ewing 2012 and REECUR) for Ewing Sarcoma (ES) patients across Europe

**Name of the conference:** CTOS - 2016 Annual Meeting

**Corresponding author:** No

**City of event:** Lisbon, Portugal

**Date of event:** 09/11/2016

**End date:** 12/11/2016

**Organising entity:** CTOS

Bernardette Brennan; Martin McCabe; Jennifer Anderton; Perrine Marec Bérard; Uta T. Dirksen; Javier Martin; Kirsten Sundby Hall; Jukka Jukka Kanerva; Stefano Ferrari; Hans Gelderblom; Veronica Moroz; Nicola Fenwick; Sandra Strauss; Jeremy Whelan; Keith Wheatley.

- 10** **Title of the work:** Epithelioid hemangioendotelioma: a retrospective analysis from the Spanish Group for Sarcoma Research (GEIS).

**Name of the conference:** Connective Tissue Oncology Society (CTOS) Annual Meeting

**Date of event:** 2015

**City organizing entity:** Salt Lake City (UT)- EEUU,

N Hindi; J Cruz; R Alvarez; JM Cano; A Gutierrez; J Martinez; A Lopez-Pousa; JA Lopez; P Luna; L González de Sande; M Blanco; J Lavernia; S Martín-Algarra; J Martinez-Trufero; J. Martin-Broto.



- 11 Title of the work:** Estudio del potencial antitumoral de un nuevo fármaco diana en sarcomas.  
**Name of the conference:** I Jornada de Proyectos Piloto en Investigación Biomédica HUSE  
**Date of event:** 2015  
Silvia Calabuig-Fariñas; Irene Felipe-Abrio; Antònia Obrador-Hevia; Aina Martín; Regina Alemany; Rafael Ramos; Javier Martín-Broto.
- 12 Title of the work:** Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study  
**Name of the conference:** 15th ASEICA INTERNATIONAL CONGRESS  
**Date of event:** 2015  
Cristina Tous; Andrés Redondo; Claudia María Valverde; María Ángeles Vaz Salgado; Jaume Mora; Xavier Garcia Del Muro; Maria Pilar Sancho Marquez; Javier Martinez-Trufero; Robert Diaz Beveridge; Pilar Blay; Antonio Gutierrez; Pablo Luna Fra; Antonio Lopez-Pousa; Amancio Carnero; Javier Martin-Broto."Abstract C64, page 71, Abstracts' book".
- 13 Title of the work:** Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study  
**Name of the conference:** American Society Clinical Oncology (ASCO) Annual Meeting  
**Date of event:** 2015  
Javier Martin Broto; Andrés Redondo; Claudia María Valverde; María Ángeles Vaz Salgado; Jaume Mora; Xavier Garcia del Muro; Maria Pilar Sancho Marquez; Javier Martinez-Trufero; Robert Diaz Beveridge; Antonio Gutierrez; Pilar Blay; Cristina Tous Rivera; Pablo Luna Fra; Antonio Lopez-Pousa. "Clin Oncol 33, 2015 (suppl; abstr 147760)".
- 14 Title of the work:** Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.  
**Name of the conference:** American Society Clinical Oncology (ASCO) Annual Meeting  
**Date of event:** 2015  
Javier Martin Broto; Antonio Fernandez-Serra; Jose Duran; Silvia Calabuig-Fariñas; Antonio Gutierrez; Irene Felipe-Abrio; Dolores Sanchez-Izquierdo; Javier Martinez-Trufero; Antonio Casado Herraes; Andres Poveda; Luis Rubio Martinez; Carmen Balana; Ferran Losa; Claudia María Valverde; Jordi Rubió; Josefina Cruz; Cristina Tous Rivera; Luis Miguel Gonzalez de Sande; Ricardo Cubedo; Jose Antonio Lopez-Guerrero. "Clin Oncol 33, 2015 (suppl; abstr 151903)".
- 15 Title of the work:** Sarcoma of the foot: changes in amputation rate over one decade  
**Name of the conference:** 28th European Musculo-Skeletal Oncology Society (EMSOS) Annual Meeting  
**City of event:** ATENAS,  
**Date of event:** 2015  
O. Tendero; I. Felipe-Abrio; P. Sancho; J. Martin-Broto; I. Monge; D. Salinas; R. Ramos; I. Alastuey; P. Luna; J. Estrada; L Muntaner; A Ballesteros."Poster 106".
- 16 Title of the work:** Somatic localized angiosarcoma: a clinic-pathological series characterization from the Spanish Group for Sarcoma Research (GEIS).  
**Name of the conference:** Connective Tissue Oncology Society (CTOS) Annual Meeting  
**City of event:** Salt Lake City (UT)- EEUU,  
**Date of event:** 2015  
J Cruz; N Hindi; R Alvarez; JA López; A Gutierrez; A Lopez-Pousa; MJ Blanco; J Martinez-Trufero; JM Cano; C Valverde; J Lavernia; MA Vaz; I Sevilla; LM González de Sande; J Martin-Broto.
- 17 Title of the work:** Targeting neddylation of Cullin-RING Ligases by MLN4924® decreases cell proliferation and survival of soft tissue sarcoma cells.  
**Name of the conference:** 15th ASEICA INTERNATIONAL CONGRESS  
**Date of event:** 2015





Irene Felipe-Abrio; Antònia Obrador-Hevia; Aina Martín; Silvia Calabuig-Fariñas; Regina Alemany; Javier Martín. "Abstract B37, page 55, Abstracts' book".

- 18 Title of the work:** Visceral angiosarcoma series: differential behavior between breast angiosarcomas and other locations. A Spanish Group for Sarcoma Research (GEIS) study  
**Name of the conference:** Connective Tissue Oncology Society (CTOS) Annual Meeting  
**City of event:** Salt Lake City (UT)- EEUU,  
**Date of event:** 2015  
J Cruz; N Hindi; R Alvarez; JA López; A Gutierrez; A Lopez-Pousa; J Martinez-Trufero; JM Cano; C Valverde; J Martínez; J Rubió; A Sala; A Perez-Fidalgo; J. Martin-Broto.
- 19 Title of the work:** Wnt/?-catenin signalling inhibition is a potential new therapeutic strategy in soft tissue sarcomas.  
**Name of the conference:** Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic, European Association for Cancer Research.  
**Date of event:** 2015  
Antònia Obrador Hevia; Esther Martínez; Silvia Calabuig Fariñas; Rafael Ramos; Irene Felipe Abrio; Javier Martín Broto; Regina Alemany Alonso. "389, pp. 116. EAS 2015 | PROCEEDINGS BOOK".
- 20 Title of the work:** Wnt/?-catenin signalling inhibition is a potential new therapeutic strategy in soft tissue sarcomas. PARTICIPATION: POSTER  
**Name of the conference:** 15th ASEICA INTERNATIONAL CONGRESS  
**Date of event:** 2015  
Antònia Obrador Hevia; Esther Martínez; Silvia Calabuig Fariñas; Rafael Ramos; Irene Felipe Abrio; Javier Martín Broto; Regina Alemany Alonso. "Abstract G119, page 106, Abstracts' book".
- 21 Title of the work:** Disregulation of mir-550 and let-7e in intestinal high-risk localized GIST: A GEIS study  
**Name of the conference:** ASCO meeting  
**City of event:** Chicago,  
**Date of event:** 2014  
/AS: Jose Antonio Lopez-Guerrero; Antonio Fernandez-Serra; Silvia Calabuig; Dolors Sanchez-Izquierdo; Antonia Obrador; Jose Duran; Luis Rubio Martinez; Regina Alemany; Javier Martin Broto. "J Clin Oncol 32:5s, 2014(suppl; abstr 10514)".
- 22 Title of the work:** Nilotinib as co-adjuvant treatment with doxorubicin in sarcomas: Phase I trial results—A Spanish Group for Research on Sarcoma (GEIS) study.  
**Name of the conference:** ASCO meeting  
**City of event:** Chicago,  
**Date of event:** 2014  
/AS: Javier Martin Broto; Andrés Redondo; Javier Martinez-Trufero; Claudia María Valverde; Maria Angeles Vaz; Medina Javier; Antonia Obrador; Irene Felipe; Beatriz Castelo; Paula Hidalgo; Isabel Pajares; Jose Duran; Raul Amurrio; Regina Alemany. "J Clin Oncol 32:5s, 2014 (suppl; abstr 10573)".
- 23 Title of the work:** Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study  
**Name of the conference:** ASCO meeting  
**City of event:** Chicago,  
**Date of event:** 2014  
/AS: Xavier Garcia del Muro; Antonio Lopez-Pousa; Javier Martinez-Trufero; Javier Martin Broto; Ricardo Cubedo; Javier Lavernia; Andrés Redondo; Jose A. Lopez-Martin; Nuria Mulet-Margalef; Xavier Sanjuan; Oscar M. Tirado. "J Clin Oncol 32:5s, 2014 (suppl; abstr 10594)".

- 24** **Title of the work:** Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin—A GEIS study  
**Name of the conference:** ASCO meeting  
**City of event:** Chicago,  
**Date of event:** 2014  
*/AS:* Javier Martin Broto; Jorge Martinez-Serra; Rafael Ramos; Jose Antonio Lopez-Guerrero; Silvia Bague; Carmen Martinez; Ramiro Alvarez; Xavier Garcia del Muro; Ramon De Las Penas; Antonio Gutierrez; Javier Martinez-Trufero; Josefina Cruz; Andres Poveda; Rosa Maria Alvarez; Ricardo Cubedo; Andrés Redondo; Juan Maurel; María Ángeles Sala; Jose A. Lopez-Martin; Antonio Lopez-Pousa. "J Clin Oncol 32:5s, 2014 (suppl; abstr 10500)".
- 25** **Title of the work:** Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): the EORTC/AGITG/FSG/GEIS/ISG randomized controlled Phase III trial.  
**Name of the conference:** ASCO meeting  
**City of event:** Chicago AÑO: 2013,  
**Date of event:** 2013  
*/AS:* Paolo Giovanni Casali; Axel Le Cesne; Andres Poveda Velasco; Dusan Kotasek; Piotr Rutkowski; Peter Hohenberger; Elena Fumagalli; Ian Robert Judson; Antoine Italiano; Javier Martin Broto; Alessandro Gronchi; Angelo Paolo Dei Tos; Sandrine Marreaud; Winette T.A. Van Der Graaf; John Raymond Zalcborg; Saskia Litière; Jean-Yves Blay; EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG); French Sarcoma Group (FSG); Italian Sarcoma Group (ISG); Grupo Esp. "J Clin Oncol 31, 2013 (suppl; abstr 10500)".
- 26** **Title of the work:** MicroRNA profiling analysis in a series of high-risk intestinal GISTs  
**City of event:** Chicago,  
**Date of event:** 2013  
*/AS:* Silvia Calabuig; Javier Martin Broto; Dolores Sanchez-Izquierdo; Antonia Obrador; Luis Ortega; Antonio Casado Herraes; Claudia María Valverde; Ines de Torres; Andres Poveda; Aitziber Ugalde; Angeles Sala; Rafael Ramos; Luis Miguel Gonzalez de Sande; Ferran Losa; Nuria Lainez; Pablo Luna Fra; Josefina Cruz; Ricardo Cubedo; Jose Antonio Lopez-Guerrero; Spanish Group for Research on Sarcomas (GEIS)."Poster. J Clin Oncol 31, 2013 (suppl; abstr 10532)".
- 27** **Title of the work:** Microrna expression profile of high-risk intestinal localized gist: A GEIS study  
**Name of the conference:** . CTOS meeting  
**Type of participation:** 'Participatory - poster  
**City of event:** N York,  
**Date of event:** 2013  
*/AS:* Javier Martin-Broto, MD,PhD; Dolores Sánchez-Izquierdo; Antonia Obrador; Luis Ortega; Antonio Casado; Claudia Valverde; Andrés Poveda; Aitziber Ugalde; Angeles Sala; Rafael Ramos; Luis M. Gonzalez de Sande; Josefina Cruz; Ricardo Cubedo; José A. López-Guerrero.
- 28** **Title of the work:** Phase II trial of ifosfamide in combination with sorafenib in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.  
**Name of the conference:** ASCO meeting  
**City of event:** Chicago,  
**Date of event:** 2013  
*/AS:* Xavier Garcia del Muro; Joan Maurel; Javier Martinez Trufero; Javier Lavernia; Antonio Lopez-Pousa; Ramon De Las Penas; Ricardo Cubedo; Joaquin Fra; Antonio Casado; Ana De Juan; Laura Jimenez Colomo; Javier Martin Broto." J Clin Oncol 31, 2013 (suppl; abstr 10523)".



- 29 Title of the work:** Prognostic significance of wnt signaling pathway molecules in non-gastric GIST patients. A tissue microarray-based (TMA) analysis.  
**Name of the conference:** ASCO meeting,  
**City of event:** Chicago,  
**Date of event:** 2013  
*/AS:* Javier Martin Broto; Rafael Ramos; Javier Martinez-Trufero; Silvia Calabuig; Carlos Horndler; Antonio Casado; Luis Ortega; Luis Miguel Gonzalez de Sande; Francisco Izquierdo; Antonio Gutierrez; Angeles Sala; Aitziber Ugalde; Claudia María Valverde; Ines de Torres; Ferran Losa; Remei Blanco; Rosa Maria Sanchez Gomez; Ricardo Cubedo; Juan Antonio Carrasco; Carmen Balañá; Spanish Group for Research on Sarcomas (GEIS). "J Clin Oncol 31, 2013 (suppl; abstr 10529).".
- 30 Title of the work:** Randomized phase II trial of doxorubicin vs. trabectedin plus doxorubicin in first line treatment of patients with advanced non-resectable or metastatic soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) study  
**Name of the conference:** ECCO-ESMO meeting  
**City of event:** Amsterdam,  
**Date of event:** 2013  
*/AS:* J. Martin-Broto; A. Lopez-Pousa; X. Garcia del Muro; R. De Las Peñas; J. Martinez-Trufero; J. Cruz; R. Alvarez; R. Cubedo; A. Redondo; A. Poveda.
- 31 Title of the work:** Registry program to assess quality management in somatic soft tissue sarcoma (sts) patients. A Spanish group for research on sarcoma (GEIS) study.  
**Name of the conference:** CTOS meeting.  
**Type of participation:** 'Participatory - poster  
**City of event:** New York,  
**Date of event:** 2013  
*/AS:* Javier Martin-Broto, MD, PhD; Angeles Sala; Luis M. Gonzalez de Sande; Josefina Cruz; Antonio Gutierrez; Ana de Juan; Claudia Valverde; Pilar Blay; Javier Martinez-Trufero; Lorena Bellido; Diego Salinas; José Durán; Jordi Rubió; Ricardo Cubedo; Antonio López-Po.
- 32 Title of the work:** CUL4A gen underexpression determines worse prognosis in localized high risk soft tissue sarcoma (sts) patients of limbs or trunk wall.  
**Name of the conference:** CTOS congress  
**Type of participation:** 'Participatory - poster  
**City of event:** Praga,  
**Date of event:** 2012  
*/AS:* Javier Martin-Broto; Piero Picci; Alessandro Gronchi; Antonio López-Pousa; Stefano Ferrari; Paolo Casali; Rafael Ramos; Antonio Gutiérrez; Josefina Cruz; Ricardo Cubedo; Andrés Poveda; Silvia Calabuig; Pablo Luna; Javier Martinez Trufero and Jose Antonio López-Guerrero.
- 33 Title of the work:** Primary chemotherapy (ct) toxicity and preoperative radiation therapy (rt) in high-risk adult soft tissue sarcomas: a report from the italian sarcoma group and the spanish sarcoma group trial.  
**Name of the conference:** CTOS congress  
**City of event:** Praga,  
**Date of event:** 2012  
*/AS:* Stefano Ferrari, MD; Elena Palassini; Antonino DePaoli; Isabel Sevilla; Javier M. Trufero; Enza Barbieri; Sergio Frustaci; Alexia Bertuzzi; Annalisa Nobile; Emanuela Palmerini; Silvia Stacchiotti; Paolo G. Casali; Piero Picci; Javier M. Broto; Alessandro Gronchi.
- 34 Title of the work:** Randomized, open, prospective, phase II clinical trial of doxorubicin (Doxo) vs. trabectedin plus Doxo in the first-line treatment of patients (pts) with advanced non-operable and/or metastatic soft tissue sarcomas (STS): GEIS-20 study  
**Name of the conference:** ESMO meeting,



**City of event:** Viena,

**Date of event:** 2012

/AS: J. Martin Broto; X. Garcia Del Muro; A. Lopez-Pousa; R. De Las Penas; J. Maurel; R. Cubedo; A. Redondo; J. Martinez-Trufero; J. Cruz Jurado; A.M. Poveda.

- 35** **Title of the work:** Relationship of CUL4A gene underexpression and prognosis in localized high-risk soft tissue sarcoma (STS) patients of limbs or trunk wall.  
**Name of the conference:** J Clin Oncol 30, 2012 (suppl; abstr 10079)  
**Type of participation:** 'Participatory - poster  
**City of event:** Chicago,  
**Date of event:** 2012  
**Organising entity:** ASCO Annual Meeting.  
(p.o. de firma): Javier Martin Broto; Antonio Lopez-Pousa; Rafael Ramos; Alessandro Gronchi; Paolo Giovanni Casali; Antonio Gutierrez; Piero Picci; Stefano Ferrari; Josefina Cruz; Pablo Luna Fra; Antonio Casado; Ricardo Cubedo; Roberto Lasso; Andres Poveda; Ana De Juan; Carmen Balana; Silvia Calabuig; Antonia Obrador; Jose Antonio Lopez-Guerrero.En: J Clin Oncol. 30, 2012 (suppl; abs,
- 36** **Title of the work:** The effects of denosumab on pain and analgesic use in giant cell tumor of bone (gctb): updated results from a phase 2 study  
**Name of the conference:** CTOS congress,  
**City of event:** Praga,  
**Date of event:** 2012  
/AS: Javier Martin Broto; Charles Cleeland; Keith Skubitz; Arthur Staddon; Ronald Blum; Scott Schuetze; Martin Dominkus; Jacob Engellau; Kristin Ganjoo; Carolyn Atchison; Yi Qian; Ira Jacobs.
- 37** **Title of the work:** A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial. study.Entitat organitzadora /  
**City of event:** Chicago,  
**Date of event:** 2011  
**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 47th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po  
/as A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Bala a, J. Lavernia, J. C; T tol /. 03/2007.
- 38** **Title of the work:** Denosumab Safety and Efficacy in Giant Cell Tumor of Bone (GCTB): InterimResults From A Phase 2 Study Entitat organitzadora /  
**City of event:** Chicago,  
**Date of event:** 2011  
**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 47th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po  
/as: Jean-Yves Blay; Sant Chawla; Javier Martin Broto; Edwin Choy; Martin Dominkus; Jacob Engellau; Robert Grimer; Robert Henshaw; Emanuela Palmerini; Peter Reichardt; Piotr Rutkowski; Keith Skubitz; David Thomas; Yufan Zhao; Yi Qian; Ira Jacobs T tol /. 03/2007.
- 39** **Title of the work:** Glicoproteina-p (p-gp) y multi-drug resistance protein-1 (mrp-1) como factores pron sticos en sarcomas localizados de alto riesgo  
**Name of the conference:** Sociedad Esp  
**City of event:** M laga A O: 19-21 Octubre 2011,  
**Date of event:** 2011



/AS: Javier Martín-Broto; Pablo Luna; Antonio López-Pousa; Rafael Ramos; Antonio Gutiérrez; Raquel de Andrés; Andrés Poveda; Josefina Cruz; Roberto Lasso; Silvia Bagué.

- 40 Title of the work:** KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients  
**Name of the conference:** American Society of Clinical Oncology. 47th annual meeting ASCO.  
**City of event:** Chicago,  
**Date of event:** 2011  
/AS: J. Martin Broto; X. Garcia del Muro; A. Gutierrez; J. Martinez-Trufero; T. Serrano; J. Rubió; N. Lainez; I. Sevilla; J. Cruz; R. Ramos; L. Ortega; A. Poveda; M. Ramirez; R. Cubedo; J. Lopez-Guerrero. "J Clin Oncol 29: 2011 (suppl; abstr 10047)".
- 41 Title of the work:** Multi-drug resistance protein-1 (mrp-1) expression determine worse prognosis in high-risk, locally advanced soft tissue sarcoma (sts) patients. .Entitat organitzadora /  
**City of event:** Chicago,  
**Date of event:** 2011  
**Organising entity:** Combined Meeting of the Connective Tissue Oncology Society and Musculoskeletal Tumor Society. Congrès / Congreso: CTOS annual meeting Tipus de contribució (pòster, comunicació oral, ponència, etc.)  
/as: Javier Martin-Broto; Pablo Luna; Antonio López-Pousa; Rafael Ramos; Alessandro Gronchi; Paolo Casali; Antonio Gutiérrez; Antonio Casado; Carmen Balañá; Roberto Lasso; Andrés Poveda; Anna de Juan; Josefina Cruz; Silvia Bagué; Jose Antonio López-Guerrero. Títol /. 2029.
- 42 Title of the work:** Quality of surgery and outcome in localized, high-risk soft tissue paper #19 sarcomas (sts) of the extremities and trunk wall after neoadjuvant treatment: exploratory analysis from a phase III randomized trial from the Italian sarcoma group and Spanish sarcoma group  
**Name of the conference:** Combined Meeting of the Connective Tissue Oncology Society and Musculoskeletal Tumor Society. CTOS annual meeting.  
**City of event:** Chicago,  
**Date of event:** 2011  
/AS: Marco Fiore, MD; Paolo Verderio; Andrea Ferraro; Joan Majò; Vittorio Quagliolo; Antonino De Paoli; Claudia Sangalli; Javier Martin; Franco Gherlinzoni; Oscar Tendero; Sara Pizzamiglio; Antonio Lopez-Pousa; Piero Picci; Paolo G. Casali; Alessandro Gronchi.
- 43 Title of the work:** REVERSAL OF P-GLYCOPROTEIN AND MRP-1 MEDIATED MULTIDRUG RESISTANCE BY NILOTINIB ENHANCES THE ANTITUMORAL EFFECT OF DOXORUBICIN IN SOFT TISSUE SARCOMAS.  
**Type of participation:** 'Participatory - poster  
**City of event:** Chicago,  
**Date of event:** 2011  
**Organising entity:** Combined Meeting of the Connective Tissue Oncology Society and the Musculoskeletal Tumor Society.  
(p.o. de firma): Regina Alemany; Victor H.Villar; Oliver Vögler; Jordi M.Serra; Antonio Gutiérrez; Antònia Obrador-Hevia; Silvia Calabuig-Fariñas; Rafael Ramos; Javier Martín.
- 44 Title of the work:** Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study  
**Name of the conference:** American Society Clinical Oncology. 47th ASCO anual meeting..  
**Type of participation:** 'Participatory - poster  
**City of event:** Chicago USA.,  
**Date of event:** 2011



/AS: J. Rubió; J. Martínez-Trufero; A. Lopez-Pousa; X. Garcia del Muro; J. Fra; A. Redondo; N. Lainez; A. Poveda; A. Casado; C. M. Valverde; A. De Juan; I. Sevilla; R. Andres; J. Cruz; M. J. Safont; J. Martin Broto; X. Garcia-Albeniz; J. Maurel. "J Clin Oncol 29: 2011 (suppl; abstr 10055).".

- 45 Title of the work:** Safety and efficacy of denosumab in giant cell tumor of bone paper #38 (gctb): second interim analysis from a phase 2 study Entitat organitzadora /  
**City of event:** Chicago,  
**Date of event:** 2011  
**Organising entity:** Combined Meeting of the Connective Tissue Oncology Society and Musculoskeletal Tumor Society. Congrès / Congreso: CTOS annual meeting Tipus de contribució (pòster, comunicació oral, ponència, etc.)  
/as: Sant Chawla; Jean-Yves Blay; Javier Martin Broto; Edwin Choy; Martin Dominkus; Jacob Engellau; Robert Grimer; Robert Henshaw; Emanuela Palmerini; Peter Reichardt1; Piotr Rutkowski; Keith Skubitz; David Thomas; Yufan Zhao; Ira Jacobs. Títol /. 2029.
- 46 Title of the work:** Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS).Entitat organitzadora /  
**City of event:** Chicago,  
**Date of event:** 2011  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 47th annual meeting ASCO Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: S. Stacchiotti; P. Verderio; A. Messina; C. Morosi; A. Ferraro; V. Quagliuolo; J. Martin; A. Comandone; G. Grignani; P. Picci; S. Frustaci; A. Gronchi; P. G. Casali. Títol /. 03/2007.
- 47 Title of the work:** La Sociedad Médica Oncológica Siglo XXI Entitat organitzadora /  
**City of event:** Monterrey, MéxicoData /,  
**Date of event:** 2010  
**Organising entity:** Sociedad Médica Oncológica Siglo XXI Congrès / Congreso: XII Congreso Internacional de la Sociedad Médica Oncológica Siglo XXI Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de  
/as: Javier Martín Títol /. 2021.
- 48 Title of the work:** Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS)  
**Name of the conference:** American Society of Clinical Oncology. 46th annual meeting ASCO.....  
**City of event:** Chicago,  
**Date of event:** 2010  
/AS: A. Gronchi; S. Frustaci; M. Mercuri; J. Martin Broto; A. Lopez-Pousa; L. Mariani; P. Verderio; V. Quagliuolo; P. G. Casali; P. Picci."J Clin Oncol 28:15s, 2010 (suppl; abstr 10003)".
- 49 Title of the work:** Nilotinib enhances the cytotoxic effect of doxorubicin through selectively inhibiting the activity and cellular expression of the multidrug resistance protein p-glycoprotein in soft tissue sarcomas  
**Name of the conference:** European Society of Medical Oncology. 35th ESMO Congress.  
**City of event:** Milan, Italy  
**Date of event:** 2010  
/AS: R. Alemany; V.H. Villar; O. Vogler; J.M. Serra; A. Gutierrez; R. Ramos; J. Martin Broto."Annals of Oncology 21 (Supplement 8): (120P) viii 42–viii62, 2010.".



- 50** **Title of the work:** Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study  
**Name of the conference:** 46th annual meeting ASCO.  
**City of event:** Chicago,  
**Date of event:** 2010  
/AS: X. Garcia del Muro; A. Lopez-Pousa; J. Martin Broto; R. Cubedo; L. Jimenez Colomo; O. Gallego; M. Provencio-Pulla."J Clin Oncol 28:15s, 2010 (suppl; abstr 10024)".
- 51** **Title of the work:** Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)  
**Name of the conference:** American Society of Clinical Oncology. 46th annual meeting ASCO...  
**Type of participation:** 'Participatory - poster  
**City of event:** Chicago,  
**Date of event:** 2010  
/AS: P. G. Casali; H. Joensuu; J. Martin Broto; X. Garcia del Muro; J. Blay; C. May; A. Pustowka; P. Reichardt. "J Clin Oncol 28:15s, 2010 (suppl; abstr TPS332^)".
- 52** **Title of the work:** Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study  
**Name of the conference:** American Society of Clinical Oncology. 46th annual meeting ASCO.  
**City of event:** Chicago,  
**Date of event:** 2010  
/AS: J. Martin Broto; X. Garcia del Muro; J. Rubio; A. Gutierrez; J. Martinez-Trufero; I. Sevilla; N. Lainez; R. Andres; R. Ramos; J. A. Lopez-Guerrero. "J Clin Oncol 28:15s, 2010 (suppl; abstr 10070)".
- 53** **Title of the work:** Low doses and 24-hour perfusion with trabectedin in heavily pretreated soft tissue sarcoma (sts) patients: a particular toxicity profile  
**Name of the conference:** CTOS.  
**Type of participation:** 'Participatory - poster  
**City of event:** Miami,  
**Date of event:** 2009  
/AS: Javier Martin-Broto; Antonio Gutierrez; Maria Ramirez; Clara Martorell; Pablo Luna; María Navarro; Regina Alemany and Jordi Martinez Serra.
- 54** **Title of the work:** Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study  
**Name of the conference:** ASCO.  
**Type of participation:** 'Participatory - poster  
**City of event:** Chicago,  
**Date of event:** 2009  
/AS: X. Garcia Del Muro; J. Fra; A. Lopez Pousa; J. Maurel; J. Martín; J. Martínez Trufero; A. Casado; J. Cruz; M. A. Gómez España; J. Lavernia. "J Clin Oncol 27:15s, 2009 (suppl; abstr 10529)".
- 55** **Title of the work:** SU14813 induces mitotic catastrophe in a wide-spectrum of tumor models independently of the expression of active Receptor Tyrosine Kinase Targets  
**Name of the conference:** ECCO 15-ESMO34 Congress, ,  
**City of event:** Berlin,  
**Date of event:** 2009  
/AS: María Navarro-Palou; Javier Martín; Teresa Ros; Antonio Gutiérrez; Carlos Saus; Rafael Ramos; Regina Alemany; Oliver Vogler; Joan Besalduch; Jordi Martínez-Serra.



- 56** **Title of the work:** Manejo clínico de los tumores del estroma gastrointestinal (GIST) Entitat organitzadora /  
**City of event:** MadridData /,  
**Date of event:** 2008  
**Organising entity:** organitzadora: Servicio de Oncología del Centro Integral Oncológico “Clara Campal”  
Congrés / Congreso: Conferencia Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribució  
/as: Javier Martín Títol / . 28/02/2008.
- 57** **Title of the work:** TIME DEPENDENCE OF CRITICAL DELETIONS AS PROGNOSTIC FACTOR FOR RELAPSE-FREE SURVIVAL (RFS) IN LOCALIZED GIST. A SPANISH GROUP FOR SARCOMA RESEARCH (GEIS) STUDY.  
**City of event:** CHICAGO, USA AÑO:,  
**Date of event:** 2008  
**Organising entity:** ASCO MEETING  
/AS: JAVIER MARTÍN BROTO. "TIME DEPENDENCE OF CRITICAL DELETIONS AS PROGNOSTIC FACTOR FOR RELAPSE-FREE SURVIVAL (RFS) IN LOCALIZED GIST. A SPANISH GROUP FOR SARCOMA RESEARCH (GEIS) STUDY.".
- 58** **Title of the work:** Tratamiento multidisciplinar de los SPB. Experiencia del grupo GEIS. Entitat organitzadora /  
**City of event:** Gran CanariaData /,  
**Date of event:** 2008  
**Organising entity:** SEOM y GEIS Congrès / Congreso: I Jornada Canaria Actualización en Sarcomas de Partes Blandas Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribució (pòster, comunicació)  
/as: Javier Martín Títol / . 2010.
- 59** **Title of the work:** Actos científicos del XI Congreso Nacional SEOM Entitat organitzadora /  
**City of event:** MadridData /,  
**Date of event:** 2007  
**Organising entity:** Sociedad Española de Oncología Médica (SEOM) Congrès / Congreso: XI Congreso Nacional SEOM Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribució (pòster, comunicació)  
/as: Javier Martín Títol / . 03/2004.
- 60** **Title of the work:** Pathological significance of deletions involving codons 557 and 558 of KIT gene in localized resected gastrointestinal stromal tumors (GIST) of intermediate and high risk: a study by the Spanish Group for Sarcoma Research (GEIS). Entitat organitzadora /  
**City of event:** Chicago 1-5,  
**Date of event:** 2007  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 43st annual meeting ASCO Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribució (pòster, comunicació oral, po  
/as: I. Romero; A. Poveda; J. Martin; A. Lopez-Pousa; C. Gomez; M. Safont; R. Andres; V. Guillem; A. Llombart-Bosch; J. Lopez-Guerrero Títol / . 01/2005.
- 61** **Title of the work:** Pathological significance of deletions involving codons 557 and 558 of KIT gene in localized resected gastrointestinal stromal tumors (GIST) of intermediate and high risk: a study by the Spanish Group for Sarcoma Research (GEIS). Entitat organitzadora /  
**City of event:** Chicago 1-5,  
**Date of event:** 2007





**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 43st annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: I. Romero; A. Poveda; J. Martin; A. Lopez-Pousa; C. Gomez; M. Safont; R. Andres; V. Guillem; A. Llombart-Bosch; J. Lopez-Guerrero T toll /. 01/2005.

**62 Title of the work:** 3er Symposium Internacional de Sarcomas Entitat organitzadora /

**City of event:** SitgesData /,

**Date of event:** 2005

**Organising entity:** Grupo GEIS Congr s / Congreso: 3er Symposium Internacional de Sarcomas Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, ponencia, etc.

/as: Javier Mart n T toll /. 04/11/2005.

**63 Title of the work:** Temozolomide in the Treatment of Gynecological Leiomyosarcoma: A Spanish Group for Research on Sarcomas (GEIS) Study Entitat organitzadora /

**City of event:** Orlando,

**Date of event:** 2005

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 41st annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: X. Garcia Del Muro; J. Fra; J. Martinez Trufero; I. Sevilla; P. Escudero; J. Cruz; J. Mart n; A. Casado; V. Arrazubi; J. Buesa T toll /. 2017.

**64 Title of the work:** Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS) Entitat organitzadora /

**City of event:** New Orleans,

**Date of event:** 2004

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 40th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: A. Lopez-Pousa; J. Buesa; A. Casado; J. Garcia Del Muro; A. Poveda; J. Maurel; J. Martin; C. Bala na; J. Martinez T toll /. 05/2008.

**65 Title of the work:** Phase II Study of Temozolomide and Cisplatin as primary treatment prior radiotherapy in newly diagnosed glioblastoma multiforme patients Entitat organitzadora /

**City of event:** New Orleans,

**Date of event:** 2004

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 37th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: C. Bala n ; A. Berrocal; J. Garc a; A. Herrero; A. L pez-Pousa; R. Yaya; J. Mart n; M. Benavides T toll /. 12/2015.

**66 Title of the work:** Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study Entitat organitzadora /

**City of event:** New Orleans,

**Date of event:** 2004

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 40th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po



/as: J. Martín; A. Poveda; A. Llombart-Bosch; R. Ramos; J. García Del Muro; J. Martínez; A. De Juan; J. Maurel; F. Losa; J. M. Buesa Títol /. 05/2008.

- 67** **Title of the work:** Phase I/II trial of doxorubicin (DX) and dose escalation prolonged infusion gemcitabine (GMC) as first line treatment in advanced soft tissue sarcomas (STS). A study of the Spanish Group for Research in Sarcomas (GEIS) Entitat organitzadora /  
**City of event:** Chicago,  
**Date of event:** 2003  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 39th annual meeting ASCO  
Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, p  
/as: A. Lopez Pousa; J. M. Buesa; J. Maurel; J. Martín; A. Casado; C. Balana; J. Garcia Del Muro; A. Poveda Títol /. 31/05/2003.
- 68** **Title of the work:** High-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (STS) patients. An analysis of prognostic factors: a study of the Spanish Group for Research on Sarcomas (GEIS) Entitat organitzadora /  
**City of event:** Orlando,  
**Date of event:** 2002  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 38th annual meeting ASCO  
Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: Juan Maurel; J M Buesa; A Lopez-Pousa; X Garcia del Muro; J Martinez-Trufero; R de las Penas; M P Escudero; J Piera; J Martín; A Casado; I Sevilla; C Balana; I Bover; J Montalar; A Poveda; J Cassinello; J Cruz; J Carles; C Camps; J Bellmunt Títol /. 2021.
- 69** **Title of the work:** Malignant gastrointestinal stromal tumors and uterine sarcomas: differences in prognostic factors for survival. A clinical approach. Study of the Spanish Group for Research on Sarcomas (GEIS) Entitat organitzadora /  
**City of event:** Orlando,  
**Date of event:** 2002  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 38th annual meeting ASCO  
Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: Javier Martín; Antonio Lopez-Pousa; Isabel Bover; Isabel Sevilla; Josefina Cruz; Jose M Buesa; M P Escudero; Remei Blanco; Andres Poveda; Antonio Casado; Javier Garcia del Muro; Joan Maurel; Jose Maria Piera; Inmaculada Maestu; Susana Casado; Joan Carles; Luis M Gonzalez; Joaquin Montalar; Javier Martínez; Ramon De Las Penas; Juli Rifa Títol /. 2021.
- 70** **Title of the work:** Sequential high-dose doxorubicin and high-dose ifosfamide in advanced previously untreated soft tissue sarcoma of the adults. A Multicenter phase II study of the Spanish Group for Research on Sarcomas (GEIS) Entitat organitzadora /  
**City of event:** New Orleans,  
**Date of event:** 2001  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 37th annual meeting ASCO  
Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: X. A. López-Pousa; J. Buesa; J. García del Muro; J. Maurel; C. Balañá; A. Casado; J. Bellmunt; A. Poveda; J. Martín; J. Martínez Trufero; R. De las Peñas; I. Bover Títol /. 12/2015.
- 71** **Title of the work:** Temozolomide as a 6-Week continuous oral schedule in advanced soft tissue sarcoma: a phase II trial of the Spanish Group for Research on Sarcomas Entitat organitzadora /  
**City of event:** New Orleans,  
**Date of event:** 2001



**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 37th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: X. Garc a del Muro; A. L pez-Pousa; JM. Buesa; J. Mart n; I. Bover; P. Escudero; A. Casado; J. Martinez Trufero; J. Maurel T tol /. 12/2015.

**72 Title of the work:** Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma: a phase II trial of the spanish group for research on sarcomas (GEIS) Entitat organitzadora /

**City of event:** Palm Beach,

**Date of event:** 2001

**Organising entity:** Connective Tissue Oncology Society (CTOS) Congr s / Congreso: CTOS Annual Meeting  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, pone

/as: X Garcia del Muro; A Lopez Pousa; J M Buesa; J Martin; A Poveda; I Bover; P Escudero; J Martinez Trufero T tol /. 01/2003.

**73 Title of the work:** First-Line Doxorubicin and scalated High-dose ifosfamide in advanced soft tissue sarcoma patients. A phase II Study of the Spanish Group for Research on Sarcomas (GEIS) Entitat organitzadora /

**City of event:** New Orleans,

**Date of event:** 2000

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 36th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: A. L pez-Pousa; J. Buesa; J. Montalar; J. Mart n; J. Maurel; X. Garc a del Muro; R. De las Pe as; J. Cruz; J. Casinello; I. Sevilla; C. Bala a; A. Casado T tol /. 2023.

**74 Title of the work:** Liposomal Doxorubicin in advanced soft tissue sarcoma patients. A phase II of the Spanish Group for Research on Sarcomas (GEIS). Entitat organitzadora /

**City of event:** Atlanta,

**Date of event:** 1999

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 35th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: A. Poveda; A. L pez-Pousa; J. Mart n; JM. Buesa; C. Bala a; D. Men ndez T tol /. 2018.

**75 Title of the work:** Nephrotoxicity of continuous infusion ifosfamide. A study of the Spanish Group for Research on Sarcomas (GEIS) Entitat organitzadora /

**City of event:** Arlington,

**Date of event:** 1999

**Organising entity:** Connective Tissue Oncology Society (CTOS) Congr s / Congreso: 5th annual meeting CTOS  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral,

/as: JM. Buesa; PG. Tejjido; M. Galbe; A. L pez-Pousa; J. Garc a del Muro; J. Mart n; A. Ant n; J. Montalar; R. De las Pe as; J. Cruz; P. Escudero; J. Fra; D. Men ndez and A. Poveda T tol /. 10/1999.

**76 Title of the work:** Phase II trial of Doxorubicin and high dose Ifosfamide(DXHDI) in advanced previously untreated soft tissue sarcoma (STS) patients. A sudy of the Spanish Group for research on Sarcomas (GEIS) Entitat organitzadora /

**City of event:** Atlanta,

**Date of event:** 1999



**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 35th annual meeting ASCO  
Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: A. L pez-Pousa; JM. Buesa; J. Montalar; J. Mart n; J. Maurel; J. Garc a del Muro; R. De las Pe as; J. Cruz; J. Casinello; I. Sevilla; C. Bala a; A. Casado; I. Bover; A. Paredes; J. Carles; A. Poveda T tol /. 2018.

**77 Title of the work:** Adjuvant dox-CMF in patients with breast cancer (BC) and four or more positive nodes (? 4+LN). Can Milan trial results be reproduced in clinical setting?Entitat organitzadora /

**City of event:** Atenas, Greece

**Date of event:** 1998

**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 23rd congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: A. Pelegr ; A. Barnadas; A. Escobedo; J. Rif ; J. Mart n; N. Lainez; M. Gil; M. Bellet; R. Rosell; J. Borr s T tol /. 11/1998.

**78 Title of the work:** Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC) Entitat organitzadora /

**City of event:** Atenas, Greece

**Date of event:** 1998

**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 23rd congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: H. Manzano; G. Esquerdo; J. Rif ; D. Aguiar; A. Arrivi; R. Pazo; J. Mart n; J. Terrasa T tol /. 11/1998.

**79 Title of the work:** First-line doxorubicin and high-dose ifosfamide (DHI) in advanced soft tissue sarcoma (STS) patients. A phase II study of the Spanish Group for Research on Sarcomas Entitat organitzadora /

**City of event:** Atenas, Greece

**Date of event:** 1998

**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 23rd congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: A. L pez-Pousa; J. Montalar; J. Buesa; J. Maurel; J. Mart n; J. Cassinello; I. Sevilla; R. De las Pe as; J. Cruz; C. Bala a T tol /. 11/1998.

**80 Title of the work:** Increase in the urinary excretion of 5-hydroxyindolacetic acid (5HIAA) after cyclophosphamide-containing chemotherapy administration Entitat organitzadora /

**City of event:** Los Angeles,

**Date of event:** 1998

**Organising entity:** American Society of Clinical Oncology Congr s / Congreso: 34th annual meeting ASCO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po

/as: V. Soriano; A. Rodriguez-Lescure; J. Mart n-Broto; S. Dominguez; I. Barnetto; JJ Cruz; V. Guill n; A. Luque. T tol /. 2019.

**81 Title of the work:** Phase II study of vinorelbine and estramustine phosphate in hormono-resistant carcinoma of the prostate (HRPC) preliminary results Entitat organitzadora /

**City of event:** Atenas, Greece

**Date of event:** 1998

**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 23rd congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po



/as: J. Carles; R. Bastus; J. Martín-Broto; M. Nogué; J. Tabernero; R. Salazar; A. Arcusa; M. Domenech; J. Bellmunt; A. García; J. Romero; P. Tresca Títol /. 11/1998.

- 82 Title of the work:** Treatment with GM-CSF for chemotherapy induced febrile neutropenia Entitat organitzadora /  
**City of event:** Atenas, Greece  
**Date of event:** 1998  
**Organising entity:** European Society of Medical Oncology Congrès / Congreso: 23rd congress of the ESMO Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: JM García-Bueno; G. Esquerdo; A. González; D. Aguiar; J. Martín; A. Arrivi; J. Terrasa; R. Pazo; J. Rifà Títol /.
- 83 Title of the work:** Phase II trial of first-line high dose ifosfamide in advanced soft tissue sarcoma patients Entitat organitzadora /  
**City of event:** Denver,  
**Date of event:** 1997  
**Organising entity:** American Society of Clinical Oncology Congrès / Congreso: 33rd annual meeting ASCO Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: J. Buesa; A. López-Pousa; A. Antón; J. Martín; J. García del Muro; J. Bellmunt; A. Poveda; P. Escudero Títol /. 2020.
- 84 Title of the work:** Tratamiento adyuvante del adenocarcinoma de recto estadios B2 y C Entitat organitzadora /  
**City of event:** LeónData /,  
**Date of event:** 1997  
**Organising entity:** Sociedad Española de Oncología Médica (SEOM) Congrès / Congreso: VIº Congreso Nacional de Oncología Médica (SEOM) Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución  
/as: J. Martín; JM García-Bueno; A. González del Alba; G. Esquerdo; A. Arrivi; O. Pons; J. Terrasa; D. Aguiar; J. Rifà Títol /. 06/1997.
- 85 Title of the work:** Tratamiento del carcinoma renal metastásico con inmunoterapia y 5-FU Entitat organitzadora /  
**City of event:** León,  
**Date of event:** 1997  
**Organising entity:** Sociedad Española de Oncología Médica (SEOM) Congrès / Congreso: VIº Congreso Nacional de Oncología Médica (SEOM) Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución  
/as: JM García-Bueno; J. Martín; A. Arrivi; A. González del Alba; G. Esquerdo; J. Terrasa; O. Pons; J. Rifà Títol /.
- 86 Title of the work:** Brain metastasis of non-small cell lung cancer. Survival analysis Entitat organitzadora /  
**City of event:** Viena,  
**Date of event:** 1996  
**Organising entity:** European Society of Medical Oncology Congrès / Congreso: 21st congress of the ESMO Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, po  
/as: J. Martín; JM García-Bueno; J. Rifà; MA Gonzáles; G. Esquerdo; J. Terrasa; A. Arrivi; O. Pons Títol /. 01/2005.



- 87** **Title of the work:** Cisplatin and Vinorelbine in advanced non small lung cancer Entitat organitzadora /  
**City of event:** Viena,  
**Date of event:** 1996  
**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 21st congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po  
/as: J. Terrasa; J. Rif ; JM Garc a-Bueno; MA Gonz lez del Alba; G. Esquerdo; J. Mart n; A. Arrivi; O. Pons T tol /. 01/2005.
- 88** **Title of the work:** Esophageal cancer treated concurrently with FLEP chemotherapy and radiotherapy Entitat organitzadora /  
**City of event:** Viena,  
**Date of event:** 1996  
**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 21st congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po  
/as: A. Arrivi; J. Pardo; A. Marquez; JM Garc a-Bueno; J. Mart n; J Terrasa; O. Pons; J. Rif  T tol /. 01/2005.
- 89** **Title of the work:** First line high dose ifosfamide in patients with advanced soft tissue sarcoma. A phase II study of the spanish group for research on sarcomas Entitat organitzadora /  
**City of event:** Viena,  
**Date of event:** 1996  
**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 21st congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po  
/as: J. Buesa; A. L pez-Pousa; J. Garc a del Muro; A. Anton; J. Bellmunt; J. Mart n; P. Escudero T tol /. 01/2005.
- 90** **Title of the work:** Piperacillin-Tazobactam plus amikacin in the treatment of fever in neutropenic cancer patients Entitat organitzadora /  
**City of event:** Viena,  
**Date of event:** 1996  
**Organising entity:** European Society of Medical Oncology Congr s / Congreso: 22nd congress of the ESMO Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n (p ster, comunicaci n oral, po  
/as: JM Garc a-Bueno; J. Rif ; R. Mesia; A. Marquez; A. Arrivi; MJ Ros; A. Gonz lez del Alba; J Mart n; J. Terrasa T tol /. 01/2005.
- 91** **Title of the work:** Factores Supervivencia de los pacientes con met stasis cerebrales de carcinoma no microc tico de pulm n Entitat organitzadora /  
**City of event:** GranadaData /,  
**Date of event:** 1995  
**Organising entity:** Sociedad Espa ola de Oncolog a M dica (SEOM) Congr s / Congreso: V  Congreso Nacional de Oncolog a M dica (SEOM) Tipus de contribuci  (p ster, comunicaci  oral, pon ncia, etc.) / Tipo de contribuci n  
/as: J. Mart n; JM Garc a-Bueno; J. Rif ; A. Marquez; J. Terrasa; A. Arrivi; MA Gonz lez del Alba T tol /. 04/1995.
- 92** **Title of the work:** Factores pron sticos en c ncer no microc tico de pulm n. Estudio prospectivo de 356 pacientes Entitat organitzadora /  
**City of event:** Atenas, Greece  
**Date of event:** 1994



**Organising entity:** Congrés / Congreso: International congress for lung cancer Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicación oral, ponencia, etc.): Póster Pu

/as: R. Fuentes; E. Canals; J. Terrasa; J. Martín; I. Bover; A. Marquez; J. Dorca; J. Gumá; P. Viladiu; J. Rifà  
Títol /. 06/1994. ISBN 84-87748-40-6

**93 Title of the work:** Estudio de mortalidad quirúrgica en 698 pacientes con cáncer colo-rectal tratados con cirugía radical Entitat organitzadora /

**City of event:** Dijon, France

**Date of event:** 1993

**Organising entity:** Congrés / Congreso: XVIIIème reunion du groupe pour l'epidemiologie et l'enregistrement du cancer dans les pays de langue latine. Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo

J. Rifà; I. Garau; A. Avellá; P. Franch; J. Terrasa; J. Martín; A. Obrador; E. Benito Títol /. 05/1993.

**94 Title of the work:** Factores pronósticos en 408 mujeres con cáncer de mama, estadios I-III, tratadas con cirugía radical Entitat organitzadora /

**City of event:** MadridData /,

**Date of event:** 1993

**Organising entity:** Sociedad Española de Oncología Médica (SEOM) Congrés / Congreso: IVº Congreso Nacional de Oncología Médica (SEOM) Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución

J. Rifà; M. Salom; J. Terrasa; O. Pons; A. Arrivi; C. Señor; C. Bosch; J. Martín; A. Marquez Títol /. 2028. ISBN 84-87748-40-6

**95 Title of the work:** Factores pronósticos y de supervivencia en pacientes con carcinoma microcítico de pulmón, tratados con carboplatino y VP-16 Entitat organitzadora /

**City of event:** SitgesData /,

**Date of event:** 1992

**Organising entity:** Federación de Sociedades Españolas de Oncología (FESEO) Congrés / Congreso: IIº Congreso FESEO Tipus de contribució (pòster, comunicació oral, ponència, etc.) / Tipo de contribución (póster, comunicac

/as: J. Rifà; I. Bover; C. Bosch; J. Martín; J. Gumá; J. Terrasa; A. Arrivi; O. Pons Títol /. 09/2011.

## R&D management and participation in scientific committees

### R&D management

**Name of the activity:** GESTIÓN HOSPITALARIA

**Performed tasks:** Director Médico

**Entity:** Hospital Universitario Son Espases

**Start date:** 2004

**Duration:** 3 years